Document:

EX-10.19

 Exhibit 10.19 

NewLake Capital Partners, Inc. 

PLACEMENT AGENCY AGREEMENT 

[●], 2021 
 Ladenburg Thalmann &
Co. Inc. 
 277 Park Avenue; 26th Floor 

New York, NY 10172 
 Compass Point Research & Trading,
LLC 
 1055 Thomas Jefferson Street NW, Suite 303 
 Washington,
DC 20007 
 Loop Capital Markets LLC 
 111 W. Jackson Blvd.

 Chicago, IL 60604 
 Ladies and Gentlemen: 

NewLake Capital Partners, Inc., a Maryland corporation (the “Company”), and NLCP Operating Partnership, LP, a Delaware
limited partnership and the Company’s operating partnership (the “Operating Partnership”), confirm their respective agreements (this “Agreement”) with respect to the sale by the Company of the number of shares
of the Company’s common stock, par value $0.01 per share (the “Common Stock”), set forth in Schedule I, to certain investors (the “Investors”) pursuant to the terms and conditions herein. The
aforesaid shares of Common Stock to be purchased by the Investors are herein called the “Securities.” Ladenburg Thalmann & Co. Inc. (“Ladenburg”), Compass Point Research & Trading, LLC
(“Compass”) and Loop Capital Markets LLC (“Loop”) have agreed to act as the placement agents (the “Placement Agents”) in connection with such issuance and sale of the Securities. Each share of
Common Stock shall be sold to the Investors at a price of $[    ] per share (the “Offering Price”). 

The Company has filed with the Securities and Exchange Commission (the “Commission”) a registration statement on Form S-11 (No. 333-257253), including the related preliminary prospectus or prospectuses, covering the registration of the sale of the Securities under the Securities Act
of 1933, as amended (the “1933 Act”). Promptly after execution and delivery of this Agreement, the Company will prepare and file a prospectus in accordance with the provisions of Rule 430A (“Rule 430A”) of the rules
and regulations of the Commission under the 1933 Act (the “1933 Act Regulations”) and Rule 424(b) (“Rule 424(b)”) of the 1933 Act Regulations. The information included in such prospectus that was omitted from such
registration statement at the time it became effective but that is deemed to be part of such registration statement at the time it became effective pursuant to Rule 430A(b) is herein called the “Rule 430A Information.” Such
registration statement, including the amendments thereto, the exhibits thereto and any schedules thereto, at the time it became effective, and including the Rule 430A Information, is herein called the “Registration Statement.” Any
registration statement filed pursuant to Rule 462(b) of the 1933 Act Regulations is herein referred to as the “Rule 462(b) Registration Statement” and, after such filing, the term “Registration Statement” shall
include the Rule 462(b) Registration Statement. Each prospectus used prior to the effectiveness of the Registration Statement, and each prospectus that omitted the Rule 430A Information that was used after such effectiveness and prior

 
to the execution and delivery of this Agreement, is herein called a “preliminary prospectus.” The final prospectus, in the form first furnished to the Placement Agents for use in
connection with the offering of the Securities, is herein called the “Prospectus.” For purposes of this Agreement, all references to the Registration Statement, any preliminary prospectus, the Prospectus or any amendment or
supplement to any of the foregoing shall be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval system (“EDGAR”).  

Placement of the Shares by the Placement Agents will be made on a “best efforts” basis. Assuming the accuracy of the
representations, warranties and agreements in Section 4(e) and of the Investors in the Securities Purchase Agreements (as defined herein), the Placement Agents shall not tender to the Company and the Company shall not accept subscriptions in
contravention of the laws of the jurisdictions into which offers are made or subscriptions are accepted. 
 As used in this Agreement: 

“Applicable Time” means [●] [a.m./p.m.], Eastern time, on [●], 2021 or such other time as agreed
by the Company and the Placement Agents. 
 “General Disclosure Package” means any Issuer General Use Free
Writing Prospectuses issued at or prior to the Applicable Time, the prospectus that is included in the Registration Statement as of the Applicable Time and the information included on Schedule III hereto, all considered together. 

“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in Rule 433
of the 1933 Act Regulations (“Rule 433”), including without limitation any “free writing prospectus” (as defined in Rule 405 of the 1933 Act Regulations (“Rule 405”)) relating to the Securities
that is (i) required to be filed with the Commission by the Company, (ii) a “road show that is a written communication” within the meaning of Rule 433(d)(8)(i), whether or not required to be filed with the Commission, or
(iii) exempt from filing with the Commission pursuant to Rule 433(d)(5)(i) because it contains a description of the Securities or of the offering that does not reflect the final terms, in each case in the form filed or required to be filed with
the Commission or, if not required to be filed, in the form retained in the Company’s records pursuant to Rule 433(g). 

“Issuer General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is intended for
general distribution to prospective investors (other than a “bona fide electronic road show,” as defined in Rule 433) (the “Bona Fide Electronic Roadshow”), as evidenced by its being specified in Schedule
III. 
 “Issuer Limited Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is
not an Issuer General Use Free Writing Prospectus. 
 “Testing-the-Waters Communication” means any oral or written communication with potential investors undertaken in reliance on Section 5(d) of the 1933 Act. 

“Written Testing-the-Waters
Communication” means any Testing-the-Waters Communication that is a written communication within the meaning of Rule 405 under the 1933 Act. 

  
 2 

	 	1.	 Representations and Warranties. 

(a)    Representations and Warranties by the Company and the Operating Partnership. Each of the Company and the
Operating Partnership, jointly and severally, represents and warrants to each Placement Agent as of the date hereof, the Applicable Time, and the Closing Time (as defined below) and agrees with each Placement Agent, as follows: 

(i)     Registration Statement and Prospectuses. Each of the Registration Statement, any Rule 462(b)
Registration Statement and any post-effective amendment thereto has (A) been prepared by the Company in conformity with the requirements of the 1933 Act and the 1933 Act Regulations; (B) been filed with the Commission under the 1933 Act;
(C) become effective under the 1933 Act, and (D) been delivered by the Company to the Placement Agents. The Company has complied to the Commission’s satisfaction with all requests of the Commission for additional or supplemental
information. No stop order suspending the effectiveness of the Registration Statement, the Rule 462(b) Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing or suspending the use of
any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated. 

Each of the Registration Statement, any Rule 462(b) Registration Statement and any post-effective amendment thereto, conformed
and will conform in all material respects, at the time it became effective, to the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus (including the prospectus filed as part of the Registration Statement as
originally filed or as part of any amendment or supplement thereto), any supplement thereto or any prospectus wrapper prepared in connection therewith, and the Prospectus conformed in all material respects when filed with the Commission pursuant to
Rule 424(b) of the 1933 Act Regulations to the requirements of the 1933 Act and the 1933 Act Regulations. Each preliminary prospectus delivered to the Placement Agents for use in connection with this offering and the Prospectus was or will be
identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. 

(ii)    Accurate Disclosure. Neither the Registration Statement, any Rule 462(b) Registration
Statement nor any amendment thereto, at the times they became effective, at the Closing Time, contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact required to be stated
therein or necessary in order to make the statements therein not misleading. As of the Applicable Time, neither (A) the General Disclosure Package nor (B) any individual Issuer Limited Use Free Writing Prospectus, when considered together
with the General Disclosure Package, and (C) any individual Written Testing-the-Waters Communication, when considered together with the General Disclosure Package,
contained, contains or will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading. Neither the Prospectus nor any amendment or supplement thereto (including any prospectus wrapper), as of its date, at the time of any filing with the Commission pursuant to Rule 424(b), and at the Closing Time, contained, contains or
will contain an untrue statement of a material fact or omitted, omits or will omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

  
 3 

 The representations and warranties in this subsection shall not apply to
statements in or omissions from the Registration Statement (or any amendment thereto), any Rule 462(b) Registration Statement, the General Disclosure Package, any individual Issuer Limited Use Free Writing Prospectus or the Prospectus (or any
amendment or supplement thereto (including any prospectus wrapper)), made in reliance upon and in conformity with written information furnished to the Company by or on behalf of any Placement Agent specifically for inclusion therein. For purposes of
this Agreement, the only information so furnished shall be the information in the [fourth paragraph] under the heading “Plan of Distribution” (the “Placement Agent Information”). 

(iii)    Issuer Free Writing Prospectuses. Each Issuer Free Writing Prospectus conformed or will
conform in all material respects to the requirements of the 1933 Act and the 1933 Act Regulations on the date of first use, and the Company has complied with all prospectus delivery and any filing requirements applicable to such Issuer Free Writing
Prospectus pursuant to the 1933 Act Regulations. The Company has not made any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus without the prior written consent of the Placement Agents. The Company has
retained in accordance with the 1933 Act Regulations all Issuer Free Writing Prospectuses that were not required to be filed pursuant to the 1933 Act Regulations. No Issuer Free Writing Prospectus conflicts or will conflict with the information
contained in the Registration Statement or the Prospectus, and any preliminary or other prospectus deemed to be a part thereof that has not been superseded or modified. The Company has made available a Bona Fide Electronic Road Show in compliance
with Rule 433(d)(8)(ii) such that no filing of any “road show” (as defined in Rule 433(h)) is required in connection with the offering of the Securities. 

(iv)     Company Not Ineligible Issuer. The Company was not, at the time of filing of the
Registration Statement, any Rule 462(b) Registration Statement, and any post-effective amendment thereto and at the earliest time thereafter that the Company or another offering participant made a bona fide offer (within the meaning of Rule
164(h)(2) of the 1933 Act Regulations) of the Securities, and at the date hereof is not, an “ineligible issuer” (as defined in Rule 405 of the 1933 Act Regulations), without taking account of any determination by the Commission pursuant to
Rule 405 that it is not necessary that the Company be considered an ineligible issuer. 

(v)    Independent Accountants. The accountants who certified the financial statements and
supporting schedules included in the Registration Statement, the General Disclosure Package and the Prospectus are independent public accountants as required by the 1933 Act and the 1933 Act Regulations and the Public Company Accounting Oversight
Board (including the rules and regulations promulgated by such entity). Such accounting firms have not, during the periods covered by the financial statements included in the Registration Statement, the General Disclosure Package and the Prospectus,
provided to the Company any non-audit services, as such term is defined in Section 10A(g) of the Securities Exchange Act of 1934, as amended (“1934 Act”). 

(vi)    Financial Statements; Non-GAAP Financial Measures.
The historical financial statements (including the related notes and supporting schedules) included in the Registration Statement, the General Disclosure Package and the Prospectus comply as 

  
 4 

 
to form in all material respects with the requirements of Regulation S-X under the 1933 Act, are accurate in all material respects and present fairly the
financial position of the Company on a consolidated basis at the dates indicated; said financial statements have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) applied on a
consistent basis throughout the periods involved. The supporting schedules, if any, present fairly in accordance with GAAP the information required to be stated therein. Any summary financial information included in the Registration Statement, the
General Disclosure Package and the Prospectus present fairly the information shown therein in all material respects and have been compiled on a basis consistent with that of the audited financial statements included therein. The financial
statements, including any statement of revenues and certain expenses, of the businesses or properties acquired or proposed to be acquired, if any, included in the Registration Statement, the General Disclosure Package or the Prospectus present
fairly in all material respects the information set forth therein, have been prepared in conformity with GAAP applied on a consistent basis, except as noted therein, and otherwise have been prepared in all material respects in accordance with the
applicable financial statement requirements of Rule 3-05 or Rule 3-14 of Regulation S-X with respect to real estate
operations acquired or to be acquired. The pro forma financial statements and the related notes thereto included in the Registration Statement, the General Disclosure Package and the Prospectus present fairly in all material respects the information
shown therein, have been prepared in accordance with the Commission’s rules and guidelines with respect to pro forma financial statements and have been properly compiled on the bases described therein, and the assumptions used in the
preparation thereof are reasonable and the adjustments used therein are appropriate to give effect to the transactions and circumstances referred to therein. The pro forma financial statements included in the Registration Statement, the General
Disclosure Package and the Prospectus comply as to form with the applicable requirements of Regulation S-X of the 1933 Act in all material respects. No other financial statements or supporting schedules of the
Company or any of its subsidiaries are required to be included in the Registration Statement, the General Disclosure Package or the Prospectus under the 1933 Act and the 1933 Act Regulations. All disclosures included in the Registration Statement,
the General Disclosure Package or the Prospectus regarding “non-GAAP financial measures” (as such term is defined by the rules and regulations of the Commission) comply in all material respects with
Regulation G of the 1934 Act and Item 10 of Regulation S-K of the 1933 Act, to the extent applicable. 

(vii)    No Material Adverse Change in Business. Since the respective dates as of which information
is given in the Registration Statement, the General Disclosure Package or the Prospectus, except as otherwise stated therein, (A) there has been no material adverse change in or affecting the business affairs, business, earnings, condition
(financial or otherwise), results of operations, stockholders’ equity, properties, management or prospects of the Company and its subsidiaries considered as one enterprise (including all of the properties of the Company and its subsidiaries),
whether or not arising in the ordinary course of business (a “Material Adverse Effect”), (B) there have been no transactions entered into by the Company or any of its subsidiaries, other than those in the ordinary course of
business, which are material with respect to such entities considered as one enterprise or incurred any liability or obligation, direct or contingent, that is material to such entities considered as one enterprise, and (C) there has been no
dividend or distribution of any kind declared, paid or made by the Company or any of its subsidiaries on any class of the capital stock or other equity interest of such entities, other than the dividend declared by the company’s board of
directors payable on [●], 2021 and except those that are consistent with past practice. 

  
 5 

 (viii)    Good Standing of the Company. The
Company has been duly organized, is validly existing and in good standing as a corporation under the laws of the State of Maryland with full corporate power and authority to own, lease and operate its properties and to conduct its business as
described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement and, as the sole general partner of the Operating Partnership, to cause the Operating
Partnership to enter into and perform the Operating Partnership’s obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and in good standing in each jurisdiction in which such
qualification is required, whether by reason of the ownership or leasing of property or the conduct of its businesses, except where the failure to be so qualified or in good standing would not, singly or in the aggregate, result in a Material
Adverse Effect. 
 (ix)    Good Standing of the Operating Partnership. The Operating Partnership
has been duly formed, is validly existing and in good standing as a limited partnership under the laws of the State of Delaware with full partnership power and authority to own, lease and operate its properties and to conduct its business as
described in the Registration Statement, the General Disclosure Package and the Prospectus and to enter into and perform its obligations under this Agreement. The Operating Partnership is duly qualified as a foreign partnership to transact business
and in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of its businesses, except where the failure to be so qualified or in good standing would not,
singly or in the aggregate, result in a Material Adverse Effect. The Company is the sole general partner of the Operating Partnership. The ownership of the Operating Partnership is as set forth in the Registration Statement, the General Disclosure
Package and the Prospectus. 
 (x)    Good Standing of Subsidiaries. Each subsidiary of the
Company has been duly organized, is validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, has corporate or similar power and authority to own, lease and operate its properties and to conduct
its business as described in the Registration Statement, the General Disclosure Package and the Prospectus, and is duly qualified to transact business and in good standing in each jurisdiction in which such qualification is required, whether by
reason of the ownership or leasing of property or the conduct of its business, except where the failure to be so qualified or in good standing would not, singly or in the aggregate, result in a Material Adverse Effect. All of the issued and
outstanding capital stock or other ownership interests of each subsidiary has been duly authorized and validly issued, is (as applicable) fully paid and non-assessable and is owned by the Company, directly or
through subsidiaries, free and clear of any security interest, mortgage, pledge, lien, encumbrance, claim or equity. None of the outstanding shares of capital stock or other ownership interests of any subsidiary was issued in violation of the
preemptive or similar rights of any securityholder of such subsidiary. The Company does not, and will not upon consummation of the offering of the Securities and the related transactions, own or control, directly or indirectly, any corporation,
association or other entity that is or will be a “significant subsidiary” (within the meaning of Rule 1-02(w) of Regulation S-X) other than the entities listed
on Exhibit 21.1 to the Registration Statement. For the purposes of this Agreement, “subsidiary” means each direct and indirect subsidiary of the Company, including, without limitation, the Operating Partnership. 

  
 6 

 (xi)    Partnership Agreement. The Agreement of
Limited Partnership of the Operating Partnership, a copy of which is filed as Exhibit 10.1 to the Registration Statement (the “Partnership Agreement”), has been duly and validly authorized by the Company, in its capacity as sole
general partner of the Operating Partnership, and has been duly executed and delivered by the Company, as general partner, and is a valid and binding agreement, enforceable in accordance with its terms, except to the extent that enforceability may
be limited by bankruptcy, insolvency, reorganization, fraudulent transfer, moratorium or similar laws affecting creditors’ rights generally and by general equitable principles and, with respect to equitable relief, the discretion of the court
before which any proceeding therefor may be brought (regardless of whether enforcement is sought in a proceeding at law or in equity) and, with respect to any indemnification provisions contained therein, except as rights under those provisions may
be limited by applicable law or policies underlying such law. 
 (xii)    Capitalization. The
authorized, issued and outstanding shares of capital stock of the Company are as set forth in the Registration Statement, the General Disclosure Package and the Prospectus under the caption “Capitalization” (except for subsequent
issuances, if any, pursuant to this Agreement, pursuant to reservations, agreements or employee benefit plans referred to in the Registration Statement, the General Disclosure Package and the Prospectus or pursuant to the exercise, redemption, or
exchange of convertible or exchangeable securities, options or warrants referred to in the Registration Statement, the General Disclosure Package and the Prospectus, including limited partner interests and preferred limited partner interests in the
Operating Partnership). The issued and outstanding shares of capital stock of the Company have been duly authorized and validly issued, are fully paid and non-assessable, conform to the description thereof
contained in the Registration Statement, General Disclosure Package and Prospectus and were issued in compliance with federal and state securities laws and not in violation of any preemptive right, resale right, right of first refusal or similar
right. The issuance of such shares of capital stock of the Company was exempt from registration or qualification under the 1933 Act and applicable state securities laws. The issued and outstanding limited partnership interests in the Operating
Partnership (the “OP Units”) have been duly authorized for issuance by the Operating Partnership to the Company and are validly issued and conform to the description thereof contained in the Registration Statement, General Disclosure
Package and Prospectus and were issued in compliance with federal and state securities laws and not in violation of any preemptive right, resale right, right of first refusal or similar right. The partnership interests in the Operating
Partnership are owned as set forth in the Registration Statement, General Disclosure Package and Prospectus. The issuance of such partnership interests in the Operating Partnership was exempt from registration or qualification under the 1933 Act and
applicable state securities laws. The Company’s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder conform in all material respects to the descriptions thereof contained in the
Registration Statement, the General Disclosure Package and the Prospectus. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, no options, warrants or other rights to purchase, agreements or other
obligations to issue, or rights to convert any obligations into or exchange any securities or interests for shares of the Company’s or its subsidiaries’ capital stock, including OP Units or other ownership interests of the Operating
Partnership or exchange any securities for shares of the Company’s capital stock are outstanding. 

  
 7 

 (xiii)    Authorization of Agreements. This
Agreement has been duly authorized, executed and delivered by the Company and the Operating Partnership. The Escrow Agreement (the “Escrow Agreement”), dated as of [●], by and among the Company, Compass Point
Research & Trading, LLC, as representative of the Placement Agents, and Cadence Bank, N.A. (the “Escrow Agent”) has been duly authorized, executed and delivered by the Company. The Securities Purchase Agreements (as defined
below) have been duly authorized and, upon delivery as contemplated by this Agreement, will be duly executed and delivered by the Company and the Operating Partnership. 

(xiv)    Authorization and Description of Securities. The Securities have been duly authorized for
issuance and sale pursuant to this Agreement and, when issued and delivered by the Company against payment therefor as provided by the Securities Purchase Agreements, shall be validly issued, fully paid and nonassessable, will conform to the
description thereof contained in the Registration Statement, General Disclosure Package and Prospectus, will be issued in compliance with federal and state securities laws and will not be issued in violation of any preemptive right, resale right,
right of first refusal or similar right. The Common Stock conforms in all material respects to all statements relating thereto contained in the Registration Statement, the General Disclosure Package and the Prospectus and such description conforms
in all material respects to the rights set forth in the instruments defining the same. No holder of Securities will be subject to personal liability solely by reason of being such a holder. If the Securities are certificated, the certificates to be
used to evidence title to the Securities, will be in substantially the form filed as an exhibit to the Registration Statement and will, at the Closing Time be substantially in such form. 

(xv)    Registration Rights. Except as described in the Registration Statement, General Disclosure
Package and Prospectus, there are no contracts, agreements or understandings between the Company and any person granting such person the right to require the Company to file a registration statement under the 1933 Act with respect to any securities
of the Company owned or to be owned by such person or to require the Company to include such securities in the securities registered pursuant to the Registration Statement or in any securities being registered pursuant to any other registration
statement filed by the Company under the 1933 Act. 
 (xvi)    Absence of Violations and Defaults.
Neither the Company nor any of its subsidiaries is (A) in violation of its charter, bylaws or similar organizational documents, (B) in default in the performance or observance of any obligation, agreement, covenant or condition contained
in any contract, indenture, mortgage, deed of trust, loan or credit agreement, note, lease, license or other agreement or instrument to which the Company or any subsidiary is a party or by which it is bound or to which any of the properties or
assets of the Company or any subsidiary is subject (collectively, “Agreements and Instruments”), except for such violations that would not, singly or in the aggregate, result in a Material Adverse Effect, or (C) except as
disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, in violation of any federal, state, local or foreign statute or rule, or any order, rule or regulation of any arbitrator, court or governmental, regulatory
or administrative agency or body or any self-regulatory organization or other non-governmental regulatory authority having jurisdiction over the Company or any of its subsidiaries or any of their respective
properties, assets or operations (each, a “Governmental Entity”). 

  
 8 

 (xvii)    Absence of Conflicts. The execution,
delivery and performance of this Agreement, the Securities Purchase Agreements, and the Escrow Agreement, the consummation of the transactions contemplated hereby, thereby and by the Registration Statement, the General Disclosure Package and the
Prospectus and the issuance and sale of the Securities (including the use of proceeds from the sale of the Securities as described in the Registration Statement, the General Disclosure Package and the Prospectus under the caption “Use of
Proceeds”) and the compliance by the Company and the Operating Partnership with their respective obligations hereunder and thereunder have been duly authorized by all necessary corporate or other action and do not and will not, whether with or
without the giving of notice or passage of time or both, conflict with or constitute a breach of, or default or Repayment Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any properties
or assets of the Company or any subsidiary pursuant to, the Agreements and Instruments (except for such conflicts, breaches, defaults or Repayment Events or liens, charges or encumbrances that would not, singly or in the aggregate, result in a
Material Adverse Effect), nor will such action result in any violation of the provisions of the charter, bylaws or similar organizational documents of the Company or any of its subsidiaries, or, except as disclosed in the Registration Statement, the
General Disclosure Package and the Prospectus, any applicable law, statute, rule, regulation, judgment, order, writ or decree of any Governmental Entity. As used herein, a “Repayment Event” means any event or condition which gives
the holder of any note, debenture or other evidence of indebtedness (or any person acting on such holder’s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of
its subsidiaries. 
 (xviii)    Absence of Labor Dispute. No labor dispute with the employees of
the Company or any subsidiary exists or, to the knowledge of the Company, is imminent, and the Company is not aware of any existing or imminent labor disturbance by the employees of any of its or any subsidiary’s principal suppliers,
manufacturers, customers or contractors, which, in either case, would result in a Material Adverse Effect. 

(xix)    Employee Benefits. (A) The Company and each of its subsidiaries or their “ERISA
Affiliates” (as defined below) are in compliance in all respects with all applicable provisions of the Employee Retirement Income Security Act of 1974, as amended, including the regulations and published interpretations thereunder
(“ERISA”); (B) no “reportable event” (as defined in ERISA) has occurred with respect to any “employee benefit plan” (as defined in ERISA) for which the Company or any of its subsidiaries or ERISA Affiliates
would have any liability; (C) the Company and each of its subsidiaries or their ERISA Affiliates have not incurred and do not reasonably expect to incur liability under Title IV of ERISA with respect to termination of, or withdrawal from, any
“employee benefit plan”; and (D) each “employee benefit plan” for which the Company and each of its subsidiaries or any of their ERISA Affiliates would have any liability that is intended to be qualified under
Section 401(a) of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (collectively, the “Code”), is so qualified in all material respects and nothing has occurred,
whether by action or by failure to act, which would cause the loss of such qualification; except, in the cases of (A), (B), and (C), as would not reasonably be expected to have a Material Adverse Effect. “ERISA Affiliate” means,
with respect to 

  
 9 

 
the Company or any of its subsidiaries, any member of any group of organizations described in Sections 414(b), (c) or (m) of the Code or Section 4001(b)(1) of ERISA of which the Company
or such subsidiary is a member. 
 (xx)    Absence of Proceedings. There is no action, suit,
proceeding, inquiry or investigation before or brought by any Governmental Entity now pending or, to the knowledge of the Company, threatened against the Company or any subsidiary, which is required to be disclosed in the Registration Statement, or
which would reasonably be expected to result in a Material Adverse Effect, or would reasonably be expected to materially and adversely affect the consummation of the transactions contemplated in any of this Agreement, the Securities Purchase
Agreements or the Escrow Agreement or the performance by the Company and the Operating Partnership of their obligations hereunder and thereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any
subsidiary is a party or of which any of their respective properties or assets is the subject which are not described in the Registration Statement, the General Disclosure Package and the Prospectus, including ordinary routine litigation incidental
to the business, would not result in a Material Adverse Effect. 
 (xxi)    Accuracy of
Descriptions. The statements made in the Registration Statement, the General Disclosure Package and the Prospectus under the caption “Description of Securities,” insofar as it purports to constitute a summary of the terms of the Common
Stock, and under the captions “Prospectus Summary—Our Company,” “Prospectus Summary—Our Properties,” “Prospectus Summary—Our Tenants,” “Prospectus Summary—The Merger,” “Prospectus
Summary—Registration Rights,” “Prospectus Summary—Government Regulation,” “Prospectus Summary—Our Operating Structure,” “Prospectus Summary—Restrictions on Ownership and Transfer,”
“Prospectus Summary—Our Tax Status,” “Prospectus Summary—Emerging Growth Company and Smaller Reporting Company Status,” “Risk Factors,” “Distribution Policy,” “Business and Properties—Our
Company,” Business and Properties—Our Properties,” “Business and Properties—Our Tenants,” “Business and Properties—Rights of First Offer,” “Business and Properties—Our Target Markets,”
“Business and Properties—The Merger,” “Business and Properties—Registration Rights,” “Business and Properties—Emerging Growth Company Status,” “Business and Properties—Governmental Regulation
and Environmental and Related Matters,” “Executive Compensation,” “Certain Relationships and Related Party Transactions,” “Policies with Respect to Certain Activities,” “Structure and Formation of Our
Company,” “Description of the Partnership Agreement of Our Operating Partnership,” “Description of Capital Stock,” “Certain Provisions of Maryland Law and of Our Charter and Bylaws,” “Shares Eligible for
Future Sale,” “Material Federal Income Tax Considerations,” and “Plan of Distribution,” insofar as such statements constitute summaries of the terms of statutes, rules or regulations, legal matters or governmental
proceedings or agreements, contracts and other documents, are accurate and fair summaries of the terms of such statutes, rules or regulations, legal matters or governmental proceedings or agreements, contracts and other documents in all material
respects. All agreements between the Company or any of its subsidiaries and any other party expressly referenced in the Registration Statement, the General Disclosure Package and the Prospectus are legal, valid and binding obligations of the Company
or such subsidiary, as applicable, enforceable against the Company or such subsidiaries, as applicable, as appropriate, in accordance with their respective terms, except to the extent that enforceability may be limited by bankruptcy, insolvency,
reorganization, fraudulent transfer, moratorium or similar laws affecting creditors’ rights generally and by general equitable principles and, with respect to 

  
 10 

 
equitable relief, the discretion of the court before which any proceeding therefor may be brought (regardless of whether enforcement is sought in a proceeding at law or in equity) and, with
respect to any indemnification provisions contained therein, except as rights under those provisions may be limited by applicable law or policies underlying such law. The Company’s operating policies, investment guidelines and other policies
described in the Registration Statement, General Disclosure Package and Prospectus accurately reflect in all material respects the current intentions of the Company with respect to the operation of its business, and no material deviation from such
guidelines or policies is currently contemplated. 
 (xxii)    Accuracy of Exhibits. There are no
legal or governmental proceedings or contracts or other documents of a character required to be described in the Registration Statement, the General Disclosure Package and the Prospectus or, in the case of documents to be filed as exhibits to the
Registration Statement, which are not described and filed as required. 
 (xxiii)    Absence of
Further Requirements. No consent, approval, authorization, license or order of, or filing or registration of or with, any Governmental Entity is necessary or required for the execution, delivery and performance by the Company or any subsidiary
of its obligations hereunder, in connection with the offering, issuance and sale of the Securities hereunder, or its consummation of the transactions contemplated by this Agreement or the Registration Statement, the General Disclosure Package and
the Prospectus, or the application of the proceeds from the sale of the Securities as described under “Use of Proceeds” in the Registration Statement, General Disclosure Package and Prospectus, except such as have been obtained or made and
except for such as have been obtained or as may be required under the 1933 Act, the 1933 Act Regulations, the rules of the OTCQX Best Market operated by OTC Markets Group, Inc. (“OTCQX”), applicable state or foreign securities laws
or the by-laws and rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”). 

(xxiv)    Possession of Licenses and Permits. Except as described in the Registration Statement, the
General Disclosure Package and the Prospectus, the Company and its subsidiaries possess such permits, licenses, approvals, consents and other authorizations (collectively, “Governmental Licenses”) issued by the appropriate
Governmental Entities necessary to conduct the business now operated by them, except where the failure so to possess would not, singly or in the aggregate, result in a Material Adverse Effect. The Company and its subsidiaries are in compliance with
the terms and conditions of all Governmental Licenses, except where the failure so to comply would not, singly or in the aggregate, result in a Material Adverse Effect. All of the Governmental Licenses are valid and in full force and effect, except
when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to be in full force and effect would not, singly or in the aggregate, result in a Material Adverse Effect. Neither the Company nor any subsidiary has
received any notice of proceedings relating to the revocation or modification of any Governmental Licenses which, singly or in the aggregate, if the subject of an unfavorable decision, ruling or finding, would result in a Material Adverse Effect.

 (xxv)    Title to Personal Property. Each of the Company and its subsidiaries have good and
marketable title to all of its assets and personal property owned by it, free and clear of all liens, encumbrances and defects, except such as are described in the Registration Statement, the General Disclosure Package and the Prospectus or such as
do 

  
 11 

 
not materially affect the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and its subsidiaries; and all assets and
personal property held under lease by the Company and its subsidiaries are held by it under valid, subsisting and enforceable leases, with such exceptions as do not materially interfere with the use made and proposed to be made of such assets by the
Company and its subsidiaries and the Company does not have notice of any material claim of any sort that has been asserted by anyone adverse to the rights of the Company and its subsidiaries under any such leases or affecting or questioning the
rights of the Company and its subsidiaries to be in the continued possession of the leased premises under such leases. 

(xxvi)    Property. (i) The Company and its subsidiaries have good and marketable fee simple
title (or in the case of ground leases, a valid leasehold interest) to all real property owned by them and the improvements (exclusive of improvements owned by tenants or by landlords, if applicable) located thereon, in each case, free and clear of
all mortgages, pledges, liens, security interests, claims, restrictions or encumbrances of any kind, except such as (A) are described in the Registration Statement, the General Disclosure Package and the Prospectus, (B) will not, singly or
in the aggregate, materially affect the value of such property and do not interfere in any material respect with the use made and proposed to be made of such property by the Company or any of its subsidiaries, or (C) would not reasonably be
expected, individually or in the aggregate, to have a Material Adverse Effect; (ii) except as otherwise set forth in or described in the Registration Statement, the General Disclosure Package and the Prospectus and except as would not,
individually or in the aggregate, reasonably be expected have a Material Adverse Effect, all of the leases and subleases of the Company and its subsidiaries, considered as one enterprise, and under which the Company or any of its subsidiaries hold
properties described in the Registration Statement, the General Disclosure Package and the Prospectus, are in full force and effect, and neither the Company nor any subsidiary has any notice of any material claim of any sort that has been asserted
by anyone adverse to the rights of the Company or any subsidiary under any of the leases or subleases mentioned above, or affecting or questioning the rights of the Company or such subsidiary to the continued possession of the leased or subleased
premises under any such lease or sublease; (iii) none of the Company or any of its subsidiaries has received from any Governmental Entities any written notice of any condemnation of or zoning change affecting the properties of the Company and
its subsidiaries or any part thereof, and none of the Company or any of its subsidiaries knows of any condemnation or zoning change affecting the properties of the Company and its subsidiaries which is threatened and, in each case, which if
consummated would reasonably be expected to, individually or in the aggregate, to have a Material Adverse Effect; (iv) each of the properties of the Company and its subsidiaries complies with all applicable codes, ordinances, laws and
regulations (including without limitation, building and zoning codes, laws and regulations and laws relating to access to the properties of the Company and its subsidiaries), except for failures to the extent disclosed in the Registration Statement,
the General Disclosure Package and the Prospectus and except for such failures to comply that would not individually or in the aggregate reasonably be expected to have a Material Adverse Effect; (v) neither the Company nor any subsidiary has
received written notice of proposed material special assessment or any proposed change in any property tax, zoning or land use law or availability of water affecting any property that would reasonably be expected, individually or in the aggregate,
to have a Material Adverse Effect; and (vi) to the knowledge of the Company and its subsidiaries, except as set forth in or described in the 

  
 12 

 
Registration Statement, the General Disclosure Package and the Prospectus or reflected in the pro forma financial statements, and except as would not, individually or in the aggregate, reasonably
be expected have a Material Adverse Effect, there are no uncured events of default, or events that with the giving of notice or passage of time, or both, would constitute an event of default, by any tenant under any of the terms and provisions of
the leases. 
 (xxvii)    No Acquisitions or Dispositions. There are no contracts, agreements,
arrangements or understandings with respect to the direct or indirect acquisition or disposition by any of the Company or its subsidiaries of interests in assets or real property that are required to be described in the Registration Statement, the
General Disclosure Package and the Prospectus that are not so described. 
 (xxviii)    Title
Insurance. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, title insurance in favor of the Company, the Operating Partnership and the subsidiaries has been obtained with respect to each
property owned by any such entity, except where the failure to maintain such title insurance would not have a Material Adverse Effect. 

(xxix)    Mortgages; Deeds of Trust. The Company has provided to the Placement Agents true and
complete copies of all indentures, credit agreements, mortgages, deeds of trust, guaranties, side letters, and other documents evidencing, securing or otherwise relating to any secured or unsecured indebtedness of the Company or any of its
subsidiaries (collectively, the “Loan Documents”), and none of the Company and its subsidiaries that is party to any of the Loan Documents is in default thereunder, nor has an event occurred which with the passage of time or the
giving of notice, or both, would become a default by any of them under any of the Loan Documents, except as otherwise set forth in the Registration Statement, the General Disclosure Package and the Prospectus, and except as would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, none of the properties owned by the Company or its subsidiaries is
encumbered by any credit agreements, mortgages, deeds of trust, guaranties, side letters, and other documents evidencing, securing or otherwise relating to any secured or unsecured indebtedness of the Company or any of its subsidiaries. 

(xxx)    Environmental Laws. Except as would not, singly or in the aggregate, result in a Material
Adverse Effect, (A) neither the Company nor any of its subsidiaries has violated or is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of common law or any judicial or
administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation, ambient air, surface water,
groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances,
petroleum or petroleum products, asbestos-containing materials, mold or any hazardous materials as defined by or regulated under any Environmental Laws, as defined below (collectively, “Hazardous Materials”) or to the manufacture,
processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, “Environmental Laws”), (B) the Company and its subsidiaries have all permits, authorizations and

  
 13 

 
approvals required under any applicable Environmental Laws and are each in compliance with their requirements, and (C) there are no pending or known threatened administrative, regulatory or
judicial actions, suits, demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries. 

(xxxi)    Accounting Controls and Disclosure Controls. The Company and each of its subsidiaries
(A) make and keep accurate books and records and (B) maintain effective internal control over financial reporting (as defined under Rule 13-a15 and 15d-15
under the rules and regulations of the Commission under the 1934 Act (the “1934 Act Regulations”)) and a system of internal accounting controls sufficient to provide reasonable assurances that (1) transactions are executed in
accordance with management’s general or specific authorization, (2) transactions are recorded as necessary to permit preparation of the Company’s financial statements in conformity with GAAP and to maintain accountability for its
assets, (3) access to the Company’s assets is permitted only in accordance with management’s general or specific authorization, and (4) the recorded accountability for the Company’s assets is compared with existing assets at
reasonable intervals and appropriate action is taken with respect to any differences. Since the Company’s incorporation, except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, there has been
(A) no material weakness in the Company’s internal control over financial reporting (whether or not remediated) and (B) no change in the Company’s internal control over financial reporting that has materially affected or is
reasonably likely to materially affect the Company’s internal control over financial reporting. Since the date of the most recent audited financial statements of the Company, except as disclosed in the Registration Statement, the General
Disclosure Package and the Prospectus, the Company has not been advised of (A) any significant deficiencies in the design or operation of internal controls that could adversely affect the ability of the Company to record, process, summarize and
report financial data, and (B) any fraud, whether or not material, that involves management or other employees who have a significant role in the internal controls of the Company. 

(xxxii)    Compliance with the Sarbanes-Oxley Act. There is and has been no failure on the part of
the Company or any of the Company’s directors or officers, in their respective capacities as such, to comply with all provisions of the Sarbanes-Oxley Act of 2002 and the rules and regulations promulgated thereunder or implementing provisions
thereof (the “Sarbanes-Oxley Act”) that are then in effect and with which the Company is required to comply as of the effectiveness of the Registration Statement, and is actively taking steps to ensure that it will be in compliance
with other provisions of the Sarbanes Oxley Act not currently in effect, upon the effectiveness of such provisions, or which will become applicable to the Company at all times after the effectiveness of the Registration Statement. 

(xxxiii)    Critical Accounting Policies. The description of the Company’s accounting policies
included in the Registration Statement, the General Disclosure Package and the Prospectus accurately and fully describe, in all material respects, (A) the accounting policies that the Company believes are the most important in the portrayal of
the Company’s financial condition and results of operations and that require management’s most difficult, subjective or complex judgments (“Critical Accounting Policies”); (B) the judgments and uncertainties
affecting the application of Critical Accounting Policies; and (C) the likelihood that materially different amounts would be reported under different conditions or using different assumptions and an explanation thereof 

  
 14 

 (xxxiv)    Federal Tax Status. Commencing with
its taxable year ended December 31, 2019, the Company has been organized and operated in conformity with the requirements for qualification and taxation as a real estate investment trust (a “REIT”) under the Code, and will
operate in a manner that will enable it to meet the requirements for qualification and taxation as a REIT under the Code. The ownership and method of operation of the Company as described in the Registration Statement and the Prospectus has enabled
the Company to meet the requirements for qualification and taxation as a REIT under the Code for the Company’s taxable years ended December 31, 2019 and 2020 and will enable the Company to meet the requirements for qualification and
taxation as a REIT under the Code for the Company’s taxable years ending December 31, 2021 and thereafter. The Company does not know of any event that would reasonably be expected to cause the Company to fail to qualify as a REIT under the
Code during any such time. All statements regarding the Company’s qualification and taxation as a REIT and descriptions of the Company’s organization, ownership and method of operation set forth in the Registration Statement, the General
Disclosure Package and the Prospectus are true, correct and complete in all material respects. Each of the Company’s direct or indirect corporate subsidiaries, if any, has been, is, and will be a “taxable REIT subsidiary” within the
meaning of Section 856(l) of the Code, and the Company is not aware of any fact that would negatively impact such qualification. Each other direct and indirect subsidiary of the Company that is not a “taxable REIT subsidiary” has been
properly treated since formation, and will continue to be properly treated, as a partnership or a disregarded entity (rather than an association or partnership taxable as a corporation) within the meaning of Section 7701 of the Code and all
applicable regulations under the Code and no election has been made to the contrary. NewLake Capital Partners, Inc., a Maryland corporation (“Target”) qualified as a REIT for U.S. federal income tax purposes for its taxable year
ended December 31, 2020 through the time of the merger with and into NL Merger Sub, LLC, a Maryland limited liability company (“Merger Sub”), a subsidiary of the Company, on or about March 17, 2021. 

(xxxv)    Payment of Taxes. The Company and its current (and with respect to (A) and (B),
former) subsidiaries (including Target) (A) have paid all material federal, state, local and foreign taxes (whether imposed directly, through withholding or otherwise and including any interest, additions to tax or penalties applicable thereto)
required to be paid through the date hereof, other than those being contested in good faith by appropriate proceedings and for which adequate reserves have been provided on the books of the applicable entity, (B) have timely filed all material
tax returns or extensions thereof required to be filed through the date hereof, and all such tax returns are correct and complete in all material respects, and (C) have adequate liquidity to pay all taxes when due and payable. The charges,
accruals and reserves on the books of the Company and its subsidiaries in respect of any income and corporation tax liability for any years not finally determined are adequate to meet any assessments or
re-assessments for additional income tax for any years not finally determined, except to the extent of any inadequacy that would not result in a Material Adverse Effect. No tax deficiency has been asserted by
a Governmental Agency against the Company or any of its current or former subsidiaries (including Target), nor does any such entity know of any tax deficiency that is likely to be asserted and, if determined adversely to any such entity, would
reasonably be expected to have a Material Adverse Effect. 

  
 15 

 (xxxvi)    Possession of Intellectual Property.
The Company and its subsidiaries own or possess adequate rights to use all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, know-how, software, systems and technology (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) necessary for the conduct of its business
as described in the Registration Statement, the General Disclosure Package and the Prospectus, and has no reason to believe that the conduct of its business will conflict with, and has not received any notice of any claim of conflict with, any such
rights of others. There is no pending or, to the knowledge of the Company, threatened action, suit, proceeding, or claim by others challenging the rights of the Company or any subsidiary in or to such rights. There is no pending or, to the
Company’s knowledge, threatened action, suit, proceeding, or claim by others that the Company or any subsidiary infringes, misappropriates, or otherwise violates any such rights of others. 

(xxxvii)    Insurance. The Company and its subsidiaries carry or are entitled to the benefits of
insurance, with financially sound and reputable insurers, in such amounts and covering such risks as is generally maintained by companies in the same or similar business, and in such amounts as is commercially reasonable for industrial properties
and dispensaries utilized in the cannabis industry, except where the failure to maintain such insurance would not have a Material Adverse Effect, and all such insurance is in full force and effect. The Company has no reason to believe that it or the
Operating Partnership will not be able (A) to renew its existing insurance coverage as and when such policies expire or (B) to obtain comparable coverage from similar institutions as may be necessary or appropriate to conduct its business
as now conducted and at a cost that would not result in a Material Adverse Effect. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which it has applied. 

(xxxviii)    Investment Company Act. Neither the Company, the Operating Partnership nor any
subsidiary is required, or upon the issuance and sale of the Securities as herein contemplated and the application of the net proceeds therefrom as described under “Use of Proceeds” in the Registration Statement, the General
Disclosure Package and the Prospectus will be required, to register as an “investment company” or an entity “controlled” by an “investment company” within the meaning of such terms under the Investment Company Act of
1940, as amended, and the rules and regulations of the Commission thereunder. 
 (xxxix)    Absence of
Manipulation. Neither the Company nor any affiliate of the Company has taken, nor will the Company or any affiliate take, directly or indirectly, any action designed to or that has constituted or that could reasonably be expected to cause or
result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Securities, and has taken no action which would directly or indirectly violate Regulation M or which would constitute a
special selling effort as such term is defined under Regulation M. 
 (xl)    Foreign Corrupt
Practices Act. None of the Company, any of its subsidiaries, or, to the knowledge of the Company, any director, officer, agent, employee, affiliate or other person acting on behalf of such entity is aware of or has taken any action, directly or
indirectly, that would result in a violation by such persons of the Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations 

  
 16 

 
thereunder (the “FCPA”), including, without limitation, making use of the mails or any means or instrumentality of interstate commerce corruptly in furtherance of an offer,
payment, promise to pay or authorization of the payment of any money, or other property, gift, promise to give, or authorization of the giving of anything of value to any “foreign official” (as such term is defined in the FCPA) or any
foreign political party or official thereof or any candidate for foreign political office, in contravention of the FCPA and the Company and, to the knowledge of the Company, its affiliates have conducted their businesses in compliance with the FCPA,
and the Company has instituted and maintains policies and procedures designed to ensure, and which are reasonably expected to continue to ensure, continued compliance by the Company and its subsidiaries therewith. 

(xli)    Money Laundering Laws. The operations of the Company and its subsidiaries are and have been
conducted at all times in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the money laundering statutes of all jurisdictions, the
rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any Governmental Entity (collectively, the “Money Laundering Laws”); and no action, suit or
proceeding by or before any Governmental Entity involving the Company or any subsidiary with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. 

(xlii)    No Conflicts with OFAC Laws. None of the Company, any of its subsidiaries or, to the
knowledge of the Company, any director, officer, agent, employee, affiliate or representatives of the Company or any of its subsidiaries is an individual or entity (“Person”) currently the subject or target of any sanctions
administered or enforced by the United States Government, including, without limitation, the U.S. Department of the Treasury’s Office of Foreign Assets Control, the United Nations Security Council, the European Union, Her Majesty’s
Treasury, or other relevant sanctions authority (collectively, “Sanctions”), nor is the Company located, organized or resident in a country or territory that is the subject of Sanctions; and the Company will not directly or
indirectly use the net proceeds of the sale of the Securities, or lend, contribute or otherwise make available such net proceeds to any subsidiaries, joint venture partners or other Person, to fund any activities of or business with any Person, or
in any country or territory, that, at the time of such funding, is the subject of Sanctions or in any other manner that will result in a violation by any Person (including any Person participating in the transaction, whether as Placement Agents,
advisor, investor or otherwise) of Sanctions. 
 (xliii)    Distribution of Offering Material. The
Company and its subsidiaries have not distributed and, prior to the later to occur of the Closing Time and the completion of the distribution of the Securities, will not distribute any offering material in connection with the offering and sale of
the Securities other than any preliminary prospectus, the Prospectus, any issuer free writing prospectus, or any other materials, if any, permitted by the 1933 Act. 

(xliv)    Restrictions on Distributions. No subsidiary of the Company is currently prohibited,
directly or indirectly, from paying any distributions to the Company or the Operating Partnership, from making any other distribution on such subsidiary’s equity interests, from repaying to the Company any loans or advances to such subsidiary
from 

  
 17 

 
the Company or from transferring any of such subsidiary’s property or assets to the Company or any other subsidiary of the Company, except as described in or contemplated by the Registration
Statement, the General Disclosure Package and the Prospectus. 
 (xlv)    Prior Sales of Common
Stock. Except as disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company has not sold, issued or distributed any shares of Common Stock. 

(xlvi)    No Equity Awards. Except for grants disclosed in the Registration Statement, the General
Disclosure Package and the Prospectus, the Company has not granted to any person or entity, a stock option or other equity-based award to purchase or receive Common Stock or OP Units pursuant to an equity-based compensation plan or otherwise. 

(xlvii)    No Finder’s Fee. Except for the Placement Agents’ fees payable by the Company
to the Placement Agents in connection with the offering of the Securities contemplated herein or as otherwise disclosed in the Registration Statement, the General Disclosure Package and the Prospectus, the Company has not incurred any liability for
any brokerage commission, finder’s fees or similar payments in connection with the offering of the Securities contemplated hereby. 

(xlviii)    OTCQX Quotation. The Securities have been approved for quotation on the OTCQX, subject
only to approval of FINRA and submission of an initial quotation by one of the Placement Agents. The Company meets the initial eligibility criteria set forth in Sections 2.1 and 2.5 of the OTCQX Rules for U.S. Companies. The Registration Statement
complies as to form with the OTCQX U.S. Disclosure Guidelines. On or before the Closing Time, the Company will post the Registration Statement through the OTC Disclosure & News Service and, assuming that such posting makes the Registration
Statement “publicly available” within the meaning of Rule 144(c) of the 1933 Act, the Registration Statement complies as to form with the requirements to make adequate current information publicly available within the meaning of Rule
144(c)(2) of the 1933 Act. The Company is not a “Blank-Check Company” within the meaning of the OTCQX Rules for U.S. Companies. 

(xlix)    Absence of Certain Relationships. No relationship, direct or indirect, exists between or
among the Company or its subsidiaries, on the one hand, and the directors, officers, stockholders, customers or suppliers of the Company, on the other hand, that is required to be described in the Registration Statement, the General Disclosure
Package and the Prospectus which is not so described. The Company has not, directly or indirectly, including through any subsidiary, extended credit, arranged to extend credit, or renewed any extension of credit, in the form of a personal loan, to
or for any executive officer of the Company or the Operating Partnership, or to or for any family member or affiliate of any director or executive officer of the Company or the Operating Partnership. 

(l)    No Integration. Neither the Company nor the Operating Partnership has sold or issued any
securities that would be integrated with the offering of the Securities contemplated by this Agreement pursuant to the 1933 Act, the 1933 Act Regulations or the interpretations thereof by the Commission. 

  
 18 

 (li)    Lending Relationship. Except as disclosed
in the Registration Statement, the General Disclosure Package and the Prospectus, the Company (A) does not have any material lending or other relationship with any bank or lending affiliate of any Placement Agent and (B) does not intend to
use any of the net proceeds from the sale of the Securities to repay any outstanding debt owed to any affiliate of any Placement Agent. 

(lii)    No Ratings. The Company has no debt securities or preferred stock that is rated by
any “nationally recognized statistical rating agency” (as such term is defined in Section 3(a)(62) of the 1934 Act ). 

(liii)    No FINRA Affiliations. There are no affiliations or associations between any member
of FINRA and any of the Company’s officers, directors or 5% or greater securityholders. 

(liv)    Statistical and Market-Related Data. All statistical and market-related data included in
the Registration Statement, the General Disclosure Package and the Prospectus are based on or derived from sources that the Company believes to be reliable and accurate, and such data agree with the sources from which they are derived, and, to the
extent required, the Company has obtained the written consent to the use of such data from such sources. 

(lv)    Emerging Growth Company. From the time of the initial confidential submission of the
Registration Statement to the Commission (or, if earlier, the first date on which the Company engaged directly or through any person authorized to act on its behalf in any
Testing-the-Waters Communication) through and including the date hereof, the Company has been and is an “emerging growth company” as defined in
Section 2(a) of the 1933 Act (an “Emerging Growth Company”). 
 (lvi)    Testing-the-Waters Communications. The Company has not distributed any Written
Testing-the-Waters Communications. 

(lvii)    Cybersecurity. With such exceptions as would not, individually or in the aggregate, have a
Material Adverse Effect: (A) there has been no security breach or incident, unauthorized access or disclosure, or other compromise of or relating to the Company’s or any of its subsidiaries’ information technology and computer
systems, networks, hardware, software, data and databases (including the data and information of their respective tenants, customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company or any of its
subsidiaries, and any such data processed or stored by third parties on behalf of the Company or any of its subsidiaries), equipment or technology (collectively, “IT Systems and Data”); (B) neither the Company nor any of its
subsidiaries has been notified of, and have no knowledge of any event or condition that would result in, any security breach or incident, unauthorized access or disclosure or other compromise to their IT Systems and Data; and (C) the Company
and its subsidiaries have implemented appropriate controls, policies, procedures and technological safeguards to maintain and protect the integrity, continuous operation, redundancy and security of their IT Systems and Data reasonably consistent
with industry standards and practices, or as required by applicable regulatory standards. The Company and its subsidiaries are presently in material compliance with all applicable laws and statutes and all judgments, orders, rules and regulations of
any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use,
access, misappropriation or modification. 

  
 19 

 (b)    Officer’s Certificates. Any certificate signed by any
officer of the Company and delivered to any Placement Agent or counsel for the Placement Agents in connection with the offering of the Securities shall be deemed a representation and warranty by the Company and the Operating Partnership, as to
matters covered thereby. 
 2.    Representations and Warranties of the Placement Agents. Each Placement Agent hereby
severally represents and warrants to the Company that: such Placement Agent is and will remain during the term of this Agreement, (i) a duly registered broker-dealer pursuant to the 1934 Act, (ii) a member in good standing of FINRA, and
(iii) duly registered as a broker-dealer under the applicable statutes and regulations of each jurisdiction in which the Securities will be offered and sold, except where registration would not be required by such laws. Other than compliance
with standard internal operating procedures, such Placement Agent is not required to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency, regulatory agency, self-regulatory
organization or stock market or any third party in order for it to execute, deliver or perform any of its obligations under this Agreement that it has not obtained or made. 
  

	 	3.	 Sale and Delivery to Placement Agents; Subscription Procedures; Closing. 

(a)    Placement Agents. On the basis of the representations, warranties and agreements of the Company and the
Operating Partnership herein contained, and subject to all the terms and conditions of this Agreement, the Placement Agents shall be the Company’s placement agents, acting on a reasonable best efforts basis, in connection with the issuance and
sale by the Company of the Securities to the Investors in a proposed offering pursuant to the Registration Statement, with the terms of the offering to be subject to market conditions and negotiations among the Company, the Placement Agents and the
prospective Investors (such offering shall be referred to herein as the “Offering”). As compensation for services rendered, and provided that any of the Securities are sold to Investors in the Offering, at the Closing Time (as
defined herein) of the Offering, the Company shall pay to the Placement Agents an amount in the aggregate equal to 6.0% of the gross proceeds received by the Company from the sale of the Securities at the Closing Time (the “Placement
Fee”). The sale of the Securities shall be made pursuant to the Registration Statement. The Company will enter into a securities purchase agreement with each Investor in the form included as Exhibit 10.21 to the Registration
Statement (the “Securities Purchase Agreement” and, collectively, the “Securities Purchase Agreements”) on the terms set forth in the General Disclosure Package. Prior to the Closing Time, a completed Securities
Purchase Agreement executed by each Investor shall have been delivered to the Company. The Company shall have the sole right to accept offers to purchase the Securities and may reject any such offer in whole or in part. 

(b)    Reasonable Best Efforts Basis. This Agreement shall not give rise to any commitment by the Placement Agents
to purchase any of the Securities, and the Placement Agents shall have no authority to bind the Company to accept offers to purchase the Securities. The Placement Agents shall act on a reasonable best efforts basis and do not guarantee that they
will be able to raise new capital in the Offering. The Placement Agents may retain other brokers or dealers to act as sub-agents on their behalf in connection with the Offering, the fees of which shall be paid
out of the Placement Fee. Prior to the earlier of (i) the date on which this Agreement is terminated and (ii) the Closing Time, the Company shall not, without the prior written consent of the Placement Agents, solicit or accept offers to
purchase shares of Common Stock (other than pursuant to the exercise of options or warrants to purchase shares of Common Stock that are outstanding at the date hereof) otherwise than through the Placement Agents in accordance herewith. 

  
 20 

 (c)    The Closing. Payment of the purchase price for, and
delivery of, the Securities shall be made at a closing (the “Closing”) at the offices of Foley & Lardner LLP, counsel for the Placement Agents, located at 100 N. Tampa Street, Suite 2700, Tampa, Florida 33602, at
10:00 a.m., Eastern time, on or before [●], 2021 or at such time on such other date as may be agreed upon in writing by the Placement Agents and the Company, but in no event later than the second (2nd) business day following the date hereof (or, if this Agreement is executed after 4:30 p.m. Eastern time, the third (3rd) business day Day) (such
time and date of payment and delivery being herein called “Closing Time”). All such actions taken at the Closing shall be deemed to have occurred simultaneously. No Securities which the Company has agreed to sell pursuant to this
Agreement and the Securities Purchase Agreements shall be deemed to have been purchased and paid for, or sold by the Company, until such Securities shall have been delivered to the Investor thereof against payment therefor by such Investor. If the
Company shall default in its obligations to deliver the Securities to an Investor whose offer it has accepted, the Company shall indemnify and hold the Placement Agents harmless against any loss, claim or damage incurred by the Placement Agents
arising from or as a result of such default by the Company. 
 (d)    Payment for the Securities. At the Closing
Time, subject to the satisfaction or waiver of the closing conditions set forth herein, the Placement Agents shall cause the Escrow Agent to pay to the Company the aggregate Offering Price (net of any fee withheld by the Placement Agents as provided
in Section 3(d)) against the Company’s delivery of the Securities to the Investors. 
 (e)    Payment of
Placement Fee. At the Closing Time, unless the Placement Agents have withheld such amounts from the Offering Price paid by the Escrow Agent, at the direction of the Placement Agents, the Company shall pay to the Placement Agents, by wire
transfer of immediately available funds to an account or accounts designated by the Placement Agents, the Placement Fee, the Blue Sky Reimbursement, the FINRA Reimbursement and the Legal Fee Reimbursement. 

(f)    Delivery of the Securities. At the Closing, the Company shall issue and sell to each Investor the number of
shares of Common Stock, and each Investor shall purchase from the Company, the number of shares of Common Stock, set forth below each purchaser’s name on the signature page of such purchaser’s Securities Purchase Agreement at a per share
price equal to the Offering Price. The Securities shall be registered in such names and in such denominations as the Placement Agents shall request by written notice to the Company. Delivery of the Securities shall be made through the facilities of
The Depository Trust Company unless the Placement Agents shall otherwise instruct. 
 4.    Covenants of the Company
and the Operating Partnership. The Company and the Operating Partnership, jointly and severally, covenant with each Placement Agent as follows: 

(a)    Compliance with Securities Regulations and Commission Requests. The Company, subject to Section 4(b),
will comply with the requirements of Rule 430A, and will notify the Placement Agents immediately, and confirm the notice in writing, (i) when any post-effective amendment to the Registration Statement shall become effective or any amendment or
supplement to the Prospectus shall have been filed, (ii) of the receipt of any comments from the Commission, (iii) of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the
Prospectus or for additional information, (iv) of the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any post-effective amendment or of any order preventing or suspending the use of
any preliminary prospectus or the Prospectus, or of the suspension of the qualification of the Securities for offering or sale in any jurisdiction, or of the initiation or threatening of any proceedings for any of such purposes or of any examination
pursuant to Section 8(e) of the 1933 Act concerning the Registration Statement and (v) if the Company becomes the subject of a proceeding under Section 8A of the 1933 Act in connection with the offering of the Securities. The

  
 21 

 
Company will effect all filings required under Rule 424(b), in the manner and within the time period required by Rule 424(b) (without reliance on Rule 424(b)(8)), and will take such steps as it
deems necessary to ascertain promptly whether the form of prospectus transmitted for filing under Rule 424(b) was received for filing by the Commission and, in the event that it was not, it will promptly file such prospectus. The Company will make
every reasonable effort to prevent the issuance of any stop order, prevention or suspension and, if any such order is issued, to obtain the lifting thereof at the earliest possible moment 

(b)    Continued Compliance with Securities Laws. The Company will comply with the 1933 Act and the 1933 Act
Regulations so as to permit the completion of the distribution of the Securities as contemplated in this Agreement and in the General Disclosure Package and the Prospectus. If at any time when a prospectus relating to the Securities is (or, but for
the exception afforded by Rule 172 of the 1933 Act Regulations (“Rule 172”), would be) required by the 1933 Act to be delivered in connection with sales of the Securities, any event shall occur or condition shall exist as a result
of which it is necessary, in the opinion of counsel for the Company, to (i) amend the Registration Statement in order that the Registration Statement will not include an untrue statement of a material fact or omit to state a material fact
required to be stated therein or necessary to make the statements therein not misleading, (ii) amend or supplement the General Disclosure Package or the Prospectus in order that the General Disclosure Package or the Prospectus, as the case may
be, will not include any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein not misleading in the light of the circumstances existing at the time it is delivered to a purchaser or
(iii) amend the Registration Statement or amend or supplement the General Disclosure Package or the Prospectus, as the case may be, in order to comply with the requirements of the 1933 Act or the 1933 Act Regulations, the Company will
(A) promptly give the Placement Agents notice of such event, (B) furnish the Placement Agents with copies of any such documents prior to such proposed filing or use, as the case may be, (C) promptly prepare any amendment or supplement
as may be necessary to correct such statement or omission or to make the Registration Statement, the General Disclosure Package or the Prospectus comply with such requirements and, a reasonable amount of time prior to any proposed filing or use,
furnish the Placement Agents with copies of any such amendment or supplement and (D) promptly file with the Commission any such amendment or supplement; provided that the Company shall not file or use any such amendment or supplement to which
the Placement Agents or counsel for the Placement Agents shall reasonably object. The Company will furnish to the Placement Agents such number of copies of such amendment or supplement as the Placement Agents may reasonably request. If at any time
when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required by the 1933 Act to be delivered in connection with sales of the Securities and following issuance of an Issuer Free Writing
Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted or would conflict with the information contained in the Registration Statement relating to the Securities or included or
would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made at that subsequent time, not
misleading, the Company will promptly notify the Placement Agents and will promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. 

(c)    Delivery of Registration Statements. The Company has furnished or will deliver to the Placement Agents and
counsel for the Placement Agents, without charge, signed electronic copies of the Registration Statement as originally filed and each amendment thereto (including electronic copies of the exhibits filed therewith) and signed electronic copies of all
consents and certificates of experts, and will also deliver to the Placement Agents, without charge, a conformed electronic copy of the Registration Statement as originally filed and each amendment thereto (without exhibits). The copies of the
Registration Statement and each amendment thereto furnished to the Placement Agents will be identical to the electronically transmitted copies thereof filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. 

  
 22 

 (d)    Delivery of Prospectuses. The Company has delivered to the
Placement Agents, without charge, as many copies of each preliminary prospectus as the Placement Agents reasonably requested, and the Company hereby consents to the use of such copies for purposes permitted by the 1933 Act. The Company will furnish
to each Placement Agent, without charge, during the period when a prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be delivered under the 1933 Act, such number of copies of the
Prospectus (as amended or supplemented) as each Placement Agent may reasonably request. The Prospectus and any amendments or supplements thereto furnished to the Placement Agents will be identical to the electronically transmitted copies thereof
filed with the Commission pursuant to EDGAR, except to the extent permitted by Regulation S-T. 

(e)    Blue Sky Qualifications. The Company will use its reasonable best efforts to qualify the Securities for
offering and sale under the applicable securities laws of such states and other jurisdictions (domestic or foreign) designated by the Placement Agents, including, without limitation, the State of New York, and will use its reasonable best efforts to
maintain such qualifications in effect so long as required to complete the distribution of the Securities. Unless necessary for the qualification or registration of the Securities pursuant to the immediately preceding sentence, the Company shall not
be obligated to (i) file any general consent to service of process or (ii) qualify as a foreign corporation or as a dealer in securities in any jurisdiction in which it is not so qualified or to subject itself to taxation in respect of
doing business in any jurisdiction in which it is not otherwise so subject. The Company will advise the Placement Agents promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Securities for
offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best
efforts to obtain the withdrawal thereof at the earliest possible moment. 
 (f)    Rule 158. The Company will
timely file such reports pursuant to the 1934 Act as are necessary in order to make generally available to its securityholders as soon as practicable an earnings statement for the purposes of, and to provide to the Placement Agents the benefits
contemplated by, the last paragraph of Section 11(a) of the 1933 Act (subject to Rule 158 under the 1933 Act). 

(g)    Use of Proceeds. The Company and the Operating Partnership will use the net proceeds from the sale of the
Securities in the manner set forth in the Registration Statement, General Disclosure Package and the Prospectus under the caption “Use of Proceeds.” 

(h)    Listing. The Company will use its best efforts to effect the quotation of the Securities on the OTCQX by the
Closing Time. 
 (i)    Restriction on Sale of Securities. During a period of 180 days from the date of the
Prospectus (the “Lock-Up Period”), the Company and the Operating Partnership will not, without the prior written consent of the Placement Agents, (i) directly or indirectly, offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase or otherwise transfer or dispose of any shares of Common Stock or any securities
convertible into or exercisable or exchangeable for Common Stock, including without limitation OP Units, or file any registration statement under the 1933 Act with respect to any of the foregoing, or (ii) enter into any swap or any other
agreement or any transaction that transfers, in whole or in part, directly or indirectly, the economic consequence of ownership of the Common Stock, whether any such swap or transaction described in clause (i) or (ii) above is to be settled by
delivery of Common Stock or such other 

  
 23 

 
securities, in cash or otherwise. The foregoing sentence shall not apply to (A) the Securities to be sold hereunder, (B) any shares of Common Stock issued by the Company upon exercise
of an option or warrant or the conversion of a security outstanding on the date hereof and referred to in the General Disclosure Package and the Prospectus, (C) any shares of Common Stock, OP Units, dividend equivalent rights or other equity
based awards issued, or options to purchase Common Stock granted, pursuant to existing employee benefit plans of the Company referred to in the General Disclosure Package and the Prospectus (including the filing of a registration statement on Form S-8 relating to such existing employee benefit plans of the Company referred to in the General Disclosure Package and the Prospectus) or (D) any shares of Common Stock or OP Units issued in connection with
acquisitions of real property; provided, however, that the recipients of shares of Common Stock or OP Units issued in connection with such an acquisition shall be required to agree in writing not to sell, offer, dispose of or otherwise transfer any
such shares of Common Stock or OP Units during the remainder of the Lock-Up Period without the prior written consent of the Placement Agents (which consent may be withheld at the sole discretion of the
Placement Agents). 
 If the Placement Agents, in their sole discretion, agree to release or waive the restrictions set forth in a lock-up agreement described in Section 7(l) hereof for an officer or director of the Company and provides the Company with notice of the impending release or waiver at least three business days before the
effective date of the release or waiver, the Company agrees to announce the impending release or waiver by a press release through a major news service at least two business days before the effective date of the release or waiver. 

(j)    Reporting Requirements. The Company will file all documents required to be filed with the Commission
pursuant to the 1934 Act within the time periods required by the 1934 Act and the 1934 Act Regulations during the period when a Prospectus relating to the Securities is (or, but for the exception afforded by Rule 172, would be) required to be
delivered under the 1933 Act. Additionally, the Company shall report the use of proceeds from the issuance of the Securities as may be required under Rule 463 under the 1933 Act. 

(k)    Issuer Free Writing Prospectuses. The Company agrees that, unless it obtains the prior written consent of
the Placement Agents, it will not make any offer relating to the Securities that would constitute an Issuer Free Writing Prospectus or that would otherwise constitute a “free writing prospectus,” or a portion thereof, required to be filed
by the Company with the Commission or retained by the Company under Rule 433; provided that the Placement Agents will be deemed to have consented to the Issuer Free Writing Prospectuses listed on Schedule III and any “road show that is a
written communication” within the meaning of Rule 433(d)(8)(i) that has been reviewed by the Placement Agents. The Company represents that it has treated or agrees that it will treat each such free writing prospectus consented to, or deemed
consented to, by the Placement Agents as an “issuer free writing prospectus,” as defined in Rule 433, and that it has complied and will comply with the applicable requirements of Rule 433 with respect thereto, including timely filing with
the Commission where required, legending and record keeping. If at any time following issuance of an Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of which such Issuer Free Writing Prospectus conflicted
or would conflict with the information contained in the Registration Statement, any preliminary prospectus or the Prospectus or included or would include an untrue statement of a material fact or omitted or would omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Placement Agents and will promptly amend or supplement, at its own expense,
such Issuer Free Writing Prospectus to eliminate or correct such conflict, untrue statement or omission. 

(l)    Absence of Manipulation. Except as contemplated herein or in the General Disclosure Package and the
Prospectus, each of the Company and the Operating Partnership will not take, 

  
 24 

 
directly or indirectly, any action designed to or that would constitute or that might reasonably be expected to cause or result in, stabilization or manipulation of the price of any securities of
the Company to facilitate the sale or resale of the Securities. 
 (m)    Qualification and Taxation as a REIT.
The Company will use its best efforts to continue to qualify for taxation as a REIT under the Code and will not take any action to revoke or otherwise terminate the Company’s REIT election, unless the Company’s board of directors
determines in good faith that it is no longer in the best interests of the Company to be so qualified. 

(n)    Transfer Agent. The Company will maintain a transfer agent and, if necessary under the jurisdiction of
formation of the Company, a registrar for its Common Stock. 
 (o)    Sarbanes-Oxley. The Company will comply
with all effective applicable provisions of the Sarbanes-Oxley Act. 
 (p)    Notification of Material Events.
The Company, during the period when the Prospectus is (or but for the exemption in Rule 172 would be) required to be delivered under the 1933 Act or the 1934 Act, shall notify the Placement Agents of the occurrence of any material events respecting
its (including those of the Operating Partnership) activities, affairs or condition, financial or otherwise, if, but only if, as a result of any such event it is necessary, in the opinion of counsel, to amend or supplement the Prospectus in order to
make the Prospectus not misleading in the light of the circumstances existing at the time it is (or but for the exemption in Rule 172 would be) delivered to a purchaser, and the Company will forthwith supply such information as shall be necessary in
the opinion of counsel to the Company and the Placement Agents for the Company to prepare any necessary amendment or supplement to the Prospectus so that, as so amended or supplemented, the Prospectus will not contain an untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at the time it is (or but for the exemption in Rule 172 would be) delivered to a purchaser, not misleading.

 (q)    Testing-the-Waters
Materials. If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of
which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact
necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Placement Agents and will promptly amend or supplement, at its own expense,
such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.  

(r)    Right of First Refusal. The Company agrees that each of Ladenburg and Compass shall have a right of first
refusal to act as the lead underwriters or placement agents for any and all future public and private equity, equity linked and debt offerings of the Company, or any successor to or any subsidiary of the Company until the actual fees generated by
Ladenburg and Compass and paid by the Company pursuant to such right of first refusal reaches $1.5 million to each of Ladenburg and Compass ($3.0 million, in the aggregate, excluding the Placement Fee paid by the Company pursuant to this
Agreement), subject to FINRA Rule 5110(g)(6). 
 (s)    Emerging Growth Company. The Company will promptly notify
the Placement Agents if the Company ceases to be an Emerging Growth Company at any time prior to the later of (i) completion of the distribution of the Securities within the meaning of the 1933 Act and (ii) completion of the 180-day restricted period referred to in Section 4(i). 

  
 25 

 5.    Representations and Warranties of Each Placement Agent.
Assuming the accuracy of the representations, warranties and agreements in Section 4(e) and of the Investors in the Securities Purchase Agreements, each Placement Agent severally represents and warrants that, such Placement Agent has solicited
offers to buy the Securities only from (i) Investors who such Placement Agent reasonably believes are Institutional Investors or (ii) “accredited investors” as such term is defined in the blue sky laws of the jurisdictions listed on
Schedule IV where the Purchaser is a bona fide resident or domiciled, as the case may be. For purposes of the Agreement, “Institutional Investors” shall mean institutional investors, institutional buyers or similar terms, as such
terms are defined in the blue sky laws of the jurisdiction where such Investors are bona fide residents or are domiciled, as the case may be, and in which offers and sales of the Securities to such Investors would not require registration or
qualification in the jurisdiction in which such Investors are bona fide residents or are domiciled. 
  

	 	6.	 Payment of Expenses. 

(a)    Expenses. The Company will pay or cause to be paid all expenses incident to the performance of its
obligations under this Agreement, including (i) the preparation, printing and filing of the Registration Statement (including financial statements and exhibits) as originally filed and each amendment thereto, (ii) the preparation, issuance
and delivery of the certificates for the Securities to the Placement Agents, including any stock, transfer or other taxes and any stamp or other duties payable upon the sale, issuance or delivery of the Securities to the Placement Agents,
(iii) the fees and disbursements of the Company’s counsel, accountants and other advisors, (iv) the qualification of the Securities under the securities laws of the several jurisdictions as provided in Section 4(e) hereof,
(v) the preparation, printing and distribution of a Blue Sky Memorandum addressing offer and sale of the Securities exclusively to certain institutional investors (including related fees and expenses of counsel to the Placement Agents in amount
not to exceed $15,000 (the “Blue Sky Reimbursement”), (vi) the preparation, printing and delivery to the Placement Agents of copies of each preliminary prospectus, each Issuer Free Writing Prospectus and the Prospectus and any amendments
or supplements thereto and any costs associated with electronic delivery of any of the foregoing by the Placement Agents to investors, (vii) the fees and expenses of any transfer agent or registrar for the Securities, (viii) the costs and
expenses of the Company relating to investor presentations on any “road show” undertaken in connection with the marketing of the Securities, including without limitation, expenses associated with the production of road show slides and
graphics, fees and expenses of any consultants engaged in connection with the road show presentations, travel and lodging expenses of the officers of the Company and any such consultants, and the cost of aircraft and other transportation chartered
or owned by the Company or its affiliates and used in connection with the road show, (ix) the filing fees incident to the review by FINRA of the terms of the sale of the Securities (including related fees and expenses of counsel to the
Placement Agents in an amount not to exceed $20,000 (the “FINRA Reimbursement”)), (x) all costs and expenses incident to the quotation of the Securities on the OTCQX , including expenses incurred by the Placement Agents in connection
therewith (including reasonable legal fees and expense of the Placement Agents’ legal counsel), (xi) the actual and reasonable out-of-pocket expenses incurred by
the Placement Agents in connection with the performance of its obligations under this Agreement (including the reasonable legal fees and expenses of the Placement Agents’ legal counsel incurred in connection with the offering contemplated by
this Agreement), up to an aggregate of $50,000 (the “Legal Fee Reimbursement”), and (xii) the costs and expenses (including, without limitation, any damages or other amounts payable in connection with legal or contractual liability)
associated with the reforming of any contracts for sale of the Securities made by the Placement Agents caused by a breach of the representation contained in the third sentence of Section 1(a)(ii). 

(b)    Placement Agents Expenses. Except to the extent otherwise provided in Section 6(a) or Section 6(c)
hereof, the Placement Agents will pay all of its own costs and expenses, including the fees and disbursements of counsel for the Placement Agents. 

  
 26 

 (c)    Termination of Agreement. If this Agreement is terminated
by the Placement Agents in accordance with the provisions of Section 7(n) or Section 11(a) hereof, the Company shall reimburse the Placement Agents for all of their
out-of-pocket expenses, including the reasonable fees and disbursements of counsel for the Placement Agents. 

7.    Conditions of Placement Agents’ Obligations. The respective obligations of the Placement Agents
hereunder are subject to the accuracy of the representations and warranties of the Company and the Operating Partnership contained herein or in certificates of any officer of the Company or any of its subsidiaries delivered pursuant to the
provisions hereof, to the performance by the Company and the Operating Partnership of their respective covenants and other obligations hereunder, and to each of the following additional terms and conditions: 

(a)    Effectiveness of Registration Statement; Rule 430A Information. The Registration Statement, including any
Rule 462(b) Registration Statement, has become effective and at the Closing Time no stop order suspending the effectiveness of the Registration Statement or any post-effective amendment thereto has been issued under the 1933 Act, no order preventing
or suspending the use of any preliminary prospectus or the Prospectus has been issued and no proceedings for any of those purposes have been instituted or are pending or, to the Company’s knowledge, contemplated; and the Company has complied
with each request (if any) from the Commission for additional information. A prospectus containing the Rule 430A Information shall have been filed with the Commission in the manner and within the time frame required by Rule 424(b) without reliance
on Rule 424(b)(8) or a post-effective amendment providing such information shall have been filed with, and declared effective by, the Commission in accordance with the requirements of Rule 430A. 

(b)    No Amendments or Supplements. No prospectus or amendment or supplement to the Registration Statement, the
Prospectus, any preliminary prospectus or any Issuer Free Writing Prospectus shall be filed to which the Placement Agents shall have reasonably objected in writing. 

(c)    Opinion of Counsel for the Company and the Operating Partnership. At the Closing Time, the Placement Agents
shall have received the favorable opinion and 10b-5 statement, dated as of the Closing Time, of Hunton Andrews Kurth LLP, counsel for the Company and the Operating Partnership, in form and substance reasonably
satisfactory to counsel for the Placement Agents, to the effect set forth in Exhibit A-1 hereto and to such further effect as counsel to the Placement Agents may reasonably request. At the Closing Time,
the Placement Agents shall have received the favorable opinion, dated as of the Closing Time, of Venable LLP, counsel for the Company and the Operating Partnership, in form and substance reasonably satisfactory to counsel for the Placement Agents,
to the effect set forth in Exhibit A-2 hereto and to such further effect as counsel to the Placement Agents may reasonably request. 

(d)    Opinion of Tax Counsel for the Company. At the Closing Time, the Placement Agents shall have received the
favorable opinion, dated as of the Closing Time, of Hunton Andrews Kurth LLP, tax counsel for the Company, in form and substance as set forth in Exhibit A-3 hereto. 

(e)    Opinion of Counsel for Placement Agents. At the Closing Time, the Placement Agents shall have received the
favorable opinion and 10b-5 statement, dated as of the Closing Time, of Foley & Lardner LLP, counsel for the Placement Agents, with respect to such matters as the Placement Agents may reasonably
request. 

  
 27 

 (f)    Accountant’s Comfort Letter; Company Financial
Information. At the time of the execution of this Agreement, the Placement Agents shall have received from each of BDO USA, LLP, Davidson & Company LLP and ACM, LLP, a letter, dated such date, in form and substance satisfactory to the
Placement Agents, containing statements and information of the type ordinarily included in accountants’ “comfort letters” to Placement Agents with respect to the financial statements and certain financial information included in the
Registration Statement, the General Disclosure Package and the Prospectus. 
 (g)    Bring-down Comfort Letter;
Company Financial Information. At the Closing Time, the Placement Agents shall have received from each of BDO USA, LLP, Davidson & Company LLP and ACM, LLP, a letter, dated as of the Closing Time, to the effect that they reaffirm the
statements made in the letters furnished pursuant to subsection (f) of this Section, except that the specified date referred to shall be a date not more than two business days prior to the Closing Time. 

(h)    Officers’ Certificate. At the Closing Time, there shall not have been, since the date hereof or since
the respective dates as of which information is given in the Registration Statement, the General Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the earnings, business affairs or
business prospects of the Company and its subsidiaries, considered as one enterprise, whether or not arising in the ordinary course of business, and the Placement Agents shall have received a certificate of the Chief Executive Officer and the Chief
Financial Officer of the Company, dated the Closing Time, to the effect set forth in Exhibit B-1 hereto. 

(i)    Certificate of the Chief Financial Officer and Chief Accounting Officer. At the time of execution of this
Agreement, the Placement Agents shall have received a certificate of the Chief Financial Officer and the Chief Accounting Officer of the Company, dated as of such date, in form and substance reasonably satisfactory to counsel for the Placement
Agents, to the effect set forth in Exhibit B-2. At the Closing Time, the Placement Agents shall have received a certificate, dated as of the Closing Time, of the Chief Financial
Officer and the Chief Accounting Officer of the Company confirming that the certificate delivered by the Company at the time of execution of this Agreement pursuant to the prior sentence of this Section 7(i) hereof remains true and correct as
of the Closing Time. 
 (j)    Approval of Quotation of Securities. The Securities shall have been approved for
quotation on the OTCQX, subject only to approval of FINRA and submission of an initial quotation by one of the Placement Agents. 

(k)    No Objection. FINRA shall not have raised any objection with respect to the fairness and reasonableness of
the underwriting terms and arrangements relating to the Offering of the Securities or the Placement Agents’ participation in the same. 

(l)    Lock-Up Agreements. At the date of this Agreement, the Placement
Agents shall have received an agreement substantially in the form of Exhibit C-1, signed by the persons listed on Schedule II (by power of attorney or otherwise). 

(m)    Additional Documents. At the Closing Time, counsel for the Placement Agents shall have been furnished with
such documents and opinions as they may require for the purpose of enabling them to pass upon the issuance and sale of the Securities as herein contemplated, or in order to evidence the accuracy of any of the representations or warranties, or the
fulfillment of any of the conditions, herein contained; and all proceedings taken by the Company in connection with the issuance and sale of the Securities as herein contemplated shall be reasonably satisfactory in form and substance to the
Placement Agents and counsel for the Placement Agents. 

  
 28 

 (n)    Termination of Agreement. If any condition specified in
this Section shall not have been fulfilled when and as required to be fulfilled, this Agreement may be terminated by the Placement Agents by notice to the Company at any time at or prior to Closing Time, and such termination shall be without
liability of any party to any other party except as provided in Section 6 and except that Sections 1, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23 shall survive any such termination and remain in full force and effect.

  

	 	8.	 Indemnification. 

(a)    Indemnification of Placement Agents. The Company and the Operating Partnership agree, jointly and severally,
to indemnify and hold harmless each Placement Agent, its affiliates (as such term is defined in Rule 501(b) under the 1933 Act (each, an “Affiliate”)), its directors, officers, employees and agents and each person, if any, who
controls any Placement Agent within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act as follows: 

(i)    against any and all loss, liability, claim, damage and expense whatsoever, as incurred, arising out
of any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement (or any amendment thereto), including the Rule 430A Information, or the omission or alleged omission therefrom of a material fact required
to be stated therein or necessary to make the statements therein not misleading or arising out of any untrue statement or alleged untrue statement of a material fact included in: any preliminary prospectus, any Issuer Free Writing Prospectus, any
Written Testing-the-Waters Communication, the General Disclosure Package, the Prospectus (or any amendment or supplement thereto), or the omission or alleged omission
therefrom of a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; 

(ii)    against any and all loss, liability, claim, damage and expense whatsoever, as incurred, to the
extent of the aggregate amount paid in settlement of any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or of any claim whatsoever based upon any such untrue statement or omission, or any
such alleged untrue statement or omission; provided that any such settlement is effected with the written consent of the Company; 

(iii)    against any and all expense whatsoever, as incurred (including the fees and disbursements of
counsel chosen by the Placement Agents), reasonably incurred in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever
based upon any such untrue statement or omission, or any such alleged untrue statement or omission, to the extent that any such expense is not paid under (i) or (ii) above; 

provided, however, that this indemnity agreement shall not apply to any loss, liability, claim, damage or expense to the extent arising out of any
untrue statement or omission or alleged untrue statement or omission made in the Registration Statement (or any amendment thereto), including the Rule 430A Information or any Issuer Free Writing Prospectus or any preliminary prospectus, the General
Disclosure Package or the Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Placement Agent Information. The indemnity agreement set forth in this Section 8(a) shall be in addition to any
liabilities that the Company or the Operating Partnership may otherwise have. 

  
 29 

 (b)    Indemnification of Company, Directors and Officers. Each
Placement Agent agrees to indemnify and hold harmless the Company, its directors, each of its officers who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of Section 15 of the 1933 Act or
Section 20 of the 1934 Act, against any and all loss, liability, claim, damage and expense described in the indemnity contained in subsection (a) of this Section, as incurred, but only with respect to untrue statements or omissions, or
alleged untrue statements or omissions, made in the Registration Statement (or any amendment thereto), including any Rule 430A Information or any preliminary prospectus, any Issuer Free Writing Prospectus, the General Disclosure Package or the
Prospectus (or any amendment or supplement thereto) in reliance upon and in conformity with the Placement Agent Information. The indemnity agreement set forth in this Section 8(b) shall be in additional to any other liabilities that the
Placement Agents may otherwise have. 
 (c)    Actions against Parties; Notification. Each indemnified party
shall give notice as promptly as reasonably practicable to each indemnifying party of any action (including any governmental investigation) commenced against it in respect of which indemnity may be sought hereunder, but failure to so notify an
indemnifying party shall not relieve such indemnifying party from any liability hereunder to the extent it is not materially prejudiced as a result thereof and in any event shall not relieve it from any liability which it may have otherwise than on
account of this indemnity agreement. The indemnifying party shall be entitled, to the extent that it shall elect, jointly with any other indemnifying party similarly notified, to assume the defense of such action, with counsel reasonably
satisfactory to the indemnified party, to represent the indemnified party and any others the indemnifying party may designate in such proceeding and shall pay the fees and disbursements of such counsel related to such proceeding. In any such
proceeding, any indemnified party shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such indemnified party unless (i) the indemnifying party and the indemnified party shall have
mutually agreed to the retention of such counsel, (ii) the indemnifying party has failed within a reasonable time to retain counsel reasonably satisfactory to the indemnified party, (iii) the indemnified party shall have reasonably
concluded that there may be legal defenses available to it that are different from or in addition to those available to the indemnifying party, or (iv) the named parties to any such proceeding (including any impleaded parties) include both the
indemnifying party and the indemnified party and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them, and in any such event the reasonable fees and expenses of one
separate counsel (and any additional local counsels) shall be paid by the indemnifying party. If the indemnifying party does not elect to assume the defense, then such firm shall be designated in writing by the Placement Agents, in the case of
parties indemnified pursuant to Section 8(a), and by the Company in the case of parties indemnified pursuant to Section 8(b). No indemnifying party shall, without the prior written consent of the indemnified parties, settle or compromise
or consent to the entry of any judgment with respect to any litigation, or any investigation or proceeding by any governmental agency or body, commenced or threatened, or any claim whatsoever in respect of which indemnification or contribution could
be sought under this Section 8 or Section 9 hereof (whether or not the indemnified parties are actual or potential parties thereto), unless such settlement, compromise or consent (i) includes an unconditional release of each
indemnified party from all liability arising out of such litigation, investigation, proceeding or claim and (ii) does not include a statement as to or an admission of fault, culpability or a failure to act by or on behalf of any indemnified
party. 
 9.    Contribution. If the indemnification provided for in Section 8 hereof is for any reason
unavailable to or insufficient to hold harmless an indemnified party in respect of any losses, liabilities, claims, damages or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount of such losses,
liabilities, claims, damages and expenses incurred by such indemnified party, as incurred, (i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Operating Partnership, on the one hand, and the
Placement Agents, on the other hand, from the offering of the Securities pursuant to this Agreement or (ii) if the allocation provided by clause 

  
 30 

 
(i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) above but also the relative fault of the
Company and the Operating Partnership, on the one hand, and of the Placement Agents, on the other hand, in connection with the statements or omissions, that resulted in such losses, liabilities, claims, damages or expenses, as well as any other
relevant equitable considerations. 
 The relative benefits received by the Company and the Operating Partnership, on the one hand, and the
Placement Agents, on the other hand, in connection with the offering of the Securities pursuant to this Agreement shall be deemed to be in the same respective proportions as the total net proceeds from the offering of the Securities pursuant to this
Agreement (before deducting expenses) received by the Company and the Operating Partnership, on the one hand, and the total placement agent fees received by the Placement Agents, on the other hand, in each case as set forth on the cover of the
Prospectus, bear to the aggregate initial public offering price of the Securities as set forth on the cover of the Prospectus. 
 The
relative fault of the Company and the Operating Partnership, on the one hand, and the Placement Agents, on the other hand, shall be determined by reference to, among other things, whether any such untrue or alleged untrue statement of a material
fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the Operating Partnership or by the Placement Agents and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission. 
 The Company, the Operating Partnership and the Placement Agents agree that
it would not be just and equitable if contribution pursuant to this Section 9 were determined by pro rata allocation (even if the Placement Agents were treated as one entity for such purpose) or by any other method of allocation which does not
take account of the equitable considerations referred to above in this Section 9. The aggregate amount of losses, liabilities, claims, damages and expenses incurred by an indemnified party and referred to above in this Section 9 shall be
deemed to include any legal or other expenses reasonably incurred by such indemnified party in investigating, preparing or defending against any litigation, or any investigation or proceeding by any governmental agency or body, commenced or
threatened, or any claim whatsoever based upon any such untrue or alleged untrue statement or omission or alleged omission. 

Notwithstanding the provisions of this Section 9, no Placement Agents shall be required to contribute any amount in excess of the amount
by which the total price at which the Securities placed by it and distributed to the public were offered to the public exceeds the amount of any damages which such Placement Agents have otherwise been required to pay by reason of any such untrue or
alleged untrue statement or omission or alleged omission. 
 No person guilty of fraudulent misrepresentation (within the meaning of
Section 11(f) of the 1933 Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. 

For purposes of this Section 9, each person, if any, who controls a Placement Agent within the meaning of Section 15 of the 1933 Act
or Section 20 of the 1934 Act and each Placement Agent’s Affiliates and selling agents shall have the same rights to contribution as such Placement Agent, and each director of the Company, each officer of the Company who signed the
Registration Statement, and each person, if any, who controls the Company or the Operating Partnership within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act shall have the same rights to contribution as the Company
or the Operating Partnership, subject in each case to the preceding two paragraphs. The Placement Agents’ obligations to contribute pursuant to this Section 9 are several, and not joint, in proportion to their respective placement
commitments as set forth opposite their respective names on Schedule I. 

  
 31 

 The provisions of this Section shall not affect any agreement among the Company and the
Operating Partnership with respect to contribution. 
 10.    Representations, Warranties and Agreements to
Survive. All representations, warranties and agreements contained in this Agreement or in certificates of officers of the Company, the Operating Partnership or any of their subsidiaries submitted pursuant hereto, shall remain operative and in
full force and effect regardless of (i) any investigation made by or on behalf of the Placement Agents or their Affiliates or selling agents, any person controlling any Placement Agent, its officers or directors, any person controlling the
Company or any person controlling the Operating Partnership and (ii) delivery of and payment for the Securities. 
  

	 	11.	 Termination of Agreement. 

(a)    Termination. The Placement Agents may terminate this Agreement, by notice to the Company, at any time at or
prior to the Closing Time (i) if there has been, in the judgment of the Placement Agents, since the time of execution of this Agreement or since the respective dates as of which information is given in the Registration Statement, the General
Disclosure Package or the Prospectus, any material adverse change in the condition, financial or otherwise, or in the properties, earnings, business affairs or business prospects of the Company and its subsidiaries considered as one enterprise,
whether or not arising in the ordinary course of business, or (ii) if there has occurred any material adverse change in the financial markets in the United States or the international financial markets, any outbreak of hostilities or escalation
thereof or other calamity or crisis, or any change or development involving a prospective change in national or international political, financial or economic conditions, in each case the effect of which is such as to make it, in the judgment of the
Placement Agents, impracticable or inadvisable to market the Securities or to enforce contracts for the sale of the Securities, or (iii) trading or quotation in any securities of or guaranteed by the Company shall have been suspended or limited
by the Commission or by The OTC Market Group, or (iv) if trading generally on the OTC Markets or any national securities exchange (including, without limitation, the NYSE American LLC, the New York Stock Exchange and the Nasdaq Stock Market)
has been suspended or limited, or minimum or maximum prices for trading have been fixed, or maximum ranges for prices have been required, by any of said exchanges or by order of the Commission, FINRA or any other governmental authority, or
(v) a material disruption has occurred in commercial banking or securities settlement or clearance services in the United States or with respect to Clearstream or Euroclear systems in Europe, or (vi) if a banking moratorium has been
declared by either federal or state authorities. 
 (b)    Liabilities. If this Agreement is terminated pursuant
to this Section, such termination shall be without liability of any party to any other party except as provided in Section 6 hereof, and provided further that Sections 1, 6, 7, 8, 9, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23 shall
survive such termination and remain in full force and effect. 
 12.    Notices. All notices and other
communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted by any standard form of telecommunication. Notices to the Placement Agents shall be directed to Ladenburg Thalmann & Co. Inc.,
277 Park Avenue, 26th Floor, New York, NY 10172, Facsimile: 212-409-2169,
E-Mail: skaplan@ladenburg.com, Attention: Steven Kaplan and to Compass Point Research & Trading, LLC, 1055 Thomas Jefferson Street NW, Suite 303, Washington, DC 20007, Facsimile:
[    ], E-mail: bhayes@compasspointllc.com, Attention: Burke Hayes, Loop Capital Markets LLC, 111 W. Jackson Blvd. Suite 1901, Chicago, IL 60604, Facsimile:
312-922-7137, E-mail: Sidney.dillard@loopcapital.com, with a copy to Foley & Lardner LLP, 100 N. Tampa Street,
Suite 2700, Tampa, Florida 33602, Facsimile: (813) 221-4210, E-mail: ccreely@foley.com, Attention: Curt Creely, Esq.; notices to the Company and the Operating
Partnership shall be directed to them at NewLake Capital Partners, Inc., 27 Pine Street, Suite 50, New Canaan, CT 

  
 32 

 
06840, Facsimile: [    ], E-mail: aconiglio@newlake.com, Attention: Anthony Coniglio; and with a copy to Hunton Andrews Kurth LLP, 2200
Pennsylvania Avenue NW, Washington, DC 20037, Facsimile: (202) 778-2201, E-mail: rsmith@hunton.com, Attention: Robert K. Smith, Esq. 

13.    Research Analyst Independence. The Company acknowledges that each Placement Agent’s research
analysts and research departments are required to be independent from their respective investment banking divisions and are subject to certain regulations and internal policies, and that each Placement Agent’s research analysts may hold views
and make statements or investment recommendations and/or publish research reports with respect to the Company and/or the offering that differ from the views of their respective investment banking divisions. The Company hereby waives and releases, to
the fullest extent permitted by law, any claims that the Company may have against any Placement Agent with respect to any conflict of interest that may arise from the fact that the views expressed by their independent research analysts and research
departments may be different from or inconsistent with the views or advice communicated to the Company by such Placement Agent’s investment banking divisions. The Company acknowledges that each Placement Agent is a full service securities firm
and as such from time to time, subject to applicable securities laws, may effect transactions for its own account or the account of its customers and hold long or short positions in debt or equity securities of the companies that may be the subject
of the transactions contemplated by this Agreement. 
 14.    No Advisory or Fiduciary Relationship. The Company
acknowledges and agrees that (a) the purchase and sale of the Securities pursuant to the Securities Purchase Agreements with the Investors, including the determination of offering price of the Securities and the determination of the Placement
Fee pursuant to this Agreement, are arm’s-length commercial transactions between the Company, on the one hand, and the Investors or the several Placement Agents, as the case may be, on the other hand,
(b) in connection with the Offering contemplated hereby and the process leading to such transaction, each Placement Agent is and has been acting solely as a principal and is not the agent or fiduciary of the Company, or its stockholders, or its
creditors, employees or any other party, (c) no Placement Agent has assumed or will assume an advisory or fiduciary responsibility in favor of the Company with respect to the Offering contemplated hereby or the process leading thereto
(irrespective of whether such Placement Agent has advised or is currently advising the Company on other matters) and no Placement Agent has any obligation to the Company with respect to the Offering contemplated hereby except the obligations
expressly set forth in this Agreement, (d) the Placement Agents and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company, and (e) the Placement Agents have
not provided any legal, accounting, regulatory or tax advice with respect to the offering contemplated hereby and the Company has consulted its own legal, accounting, regulatory and tax advisors to the extent it deemed appropriate. 

15.    Parties. This Agreement shall each inure to the benefit of and be binding upon the Placement Agents, the
Company and the Operating Partnership and their respective successors. Nothing expressed or mentioned in this Agreement is intended or shall be construed to give any person, firm or corporation, other than the Placement Agents, the Company and the
Operating Partnership and their respective successors and the controlling persons and officers and directors referred to in Sections 8 and 9 and their heirs and legal representatives, any legal or equitable right, remedy or claim under or in
respect of this Agreement or any provision herein contained. This Agreement and all conditions and provisions hereof are intended to be for the sole and exclusive benefit of the Placement Agents, the Company and the Operating Partnership and their
respective successors, and said controlling persons and officers and directors and their heirs and legal representatives, and for the benefit of no other person, firm or corporation. No purchaser of Securities from the Placement Agents shall be
deemed to be a successor by reason merely of such purchase. 

  
 33 

	 	16.	 Recognition of the U.S. Special Resolution Regimes. 

(a)    In the event that any Placement Agent is a Covered Entity and becomes subject to a proceeding under a U.S. Special
Resolution Regime, the transfer from the Placement Agents of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime
if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. 

(b)    In the event that any Placement Agent is a Covered Entity or a BHC Act Affiliate of any Placement Agent becomes
subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against the Placement Agents are permitted to be exercised to no greater extent than such Default Rights could be exercised
under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. 

For purposes of this Section 16, a “BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall
be interpreted in accordance with, 12 U.S.C. § 1841(k). “Covered Entity” means any of the following: (i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b);
(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or (iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. §
382.2(b). “Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81, 47.2 or 382.1, as applicable. “U.S. Special Resolution Regime” means each of
(i) the Federal Deposit Insurance Act and the regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. 

17.    Trial by Jury. The Company (on its behalf and, to the extent permitted by applicable law, on behalf of its
stockholders and affiliates), the Operating Partnership and each of the Placement Agents hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or
relating to this Agreement or the transactions contemplated hereby. 
 18.    Consent to Jurisdiction; Waiver
of Immunity. Any legal suit, action or proceeding arising out of or based upon this Agreement or the transactions contemplated hereby (“Related Proceedings”) shall be instituted in (i) the federal courts of the United
States of America located in the City and County of New York, Borough of Manhattan or (ii) the courts of the State of New York located in the City and County of New York, Borough of Manhattan (collectively, the “Specified
Courts”), and each party irrevocably submits to the exclusive jurisdiction (except for proceedings instituted in regard to the enforcement of a judgment of any such court (a “Related Judgment”), as to which such
jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any process, summons, notice or document by mail to such party’s address set forth above shall be effective
service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and
irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in any such court has been brought in an inconvenient forum. 

19.    GOVERNING LAW. THIS AGREEMENT AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO THIS
AGREEMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF, THE STATE OF NEW YORK, WITHOUT REGARD TO ITS CHOICE OF LAW PROVISIONS. 

  
 34 

 20.    TIME. TIME SHALL BE OF THE ESSENCE OF THIS AGREEMENT.
EXCEPT AS OTHERWISE SET FORTH HEREIN, SPECIFIED TIMES OF DAY REFER TO NEW YORK CITY TIME. 
 21.    Partial
Unenforceability. The invalidity or unenforceability of any Section, paragraph or provision of this Agreement shall not affect the validity or enforceability of any other Section, paragraph or provision hereof. If any Section, paragraph or
provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. 

22.    Counterparts. This Agreement may be executed in any number of counterparts, each of which shall be deemed to
be an original, but all such counterparts shall together constitute one and the same Agreement. 
 23.    Effect of
Headings. The Section headings herein are for convenience only and shall not affect the construction hereof. 
 [Signature page
follows] 

  
 35 

 If the foregoing is in accordance with your understanding of our agreement, please sign and
return to the Company a counterpart hereof, whereupon this instrument, along with all counterparts, will become a binding agreement among the Placement Agents, the Company and the Operating Partnership in accordance with its terms. 

 

			
	Very truly yours,
	
	NEWLAKE CAPITAL PARTNERS, INC.
		
	By:	 	  

		 	Name:
		 	Title:
	
	NLCP OPERATING PARTNERSHIP, LP
		
	By:	 	NewLake Capital Partners, Inc.,
		 	as the sole general partner
		
	By:	 	  

		 	Name:
		 	Title:

 Accepted: 

LADENBURG THALMANN & CO., INC. 

 

			
	By:	 	  

		 	Authorized Representative

  

			
	 COMPASS POINT RESEARCH &
TRADING, LLC
	 	

  

			
	By:	 	  

		 	Authorized Representative

  

			
	 LOOP CAPITAL MARKETS LLC
	 	

  

			
	By:	 	  

		 	Authorized Representativesynh-ex41_312.htm

Exhibit 4.1

SECOND SUPPLEMENTAL INDENTURE

Second Supplemental Indenture (this “Supplemental Indenture”), dated as of May 25, 2021, among each undersigned Subsidiary (the “Guaranteeing Subsidiaries”), each a subsidiary of Syneos Health, Inc. (or its permitted successor), a Delaware corporation (the “Company”), the Company, the other Guarantors (as defined in the Indenture referred to herein) and Wells Fargo Bank, National Association, as trustee under the Indenture referred to below (the “Trustee”).

W I T N E S S E T H

WHEREAS, the Company has heretofore executed and delivered to the Trustee an indenture (the “Original Indenture”), dated as of November 24, 2020 and a First Supplemental Indenture, dated as of November 24, 2020 (the “First Supplemental Indenture” and, together with the Original Indenture, the “Indenture”) providing for the issuance of 3.625% Senior Notes due 2029 (the “Notes”);

WHEREAS, the Indenture provides that under certain circumstances the Guaranteeing Subsidiaries shall execute and deliver to the Trustee a supplemental indenture pursuant to which the Guaranteeing Subsidiaries shall unconditionally guarantee all of the Company’s Obligations under the Notes and the Indenture on the terms and conditions set forth herein (the “Guarantee”); and

WHEREAS, pursuant to Section 10.01 of the First Supplemental Indenture, the Trustee is authorized to execute and deliver this Supplemental Indenture.

NOW, THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt of which is hereby acknowledged, the Guaranteeing Subsidiaries and the Trustee mutually covenant and agree for the equal and ratable benefit of the Holders of the Notes as follows:

1.Capitalized Terms.  Capitalized terms used herein without definition shall have the meanings assigned to them in the Indenture.

2.Agreement to Guarantee.  The Guaranteeing Subsidiaries hereby agree to provide an unconditional Guarantee on the terms and subject to the conditions set forth in the First Supplemental Indenture including but not limited to Article 9 thereof.

4.No Recourse Against Others.  No director, officer, employee, incorporator or stockholder of the Company or any Guarantor, as such, will have any liability for any obligations of the Company or the Guarantors under the Notes, the Indenture, the Guarantees or for any claim based on, in respect of, or by reason of, such obligations or their creation.  Each Holder of Notes by accepting a Note waives and releases all such liability.  The waiver and release are part of the consideration for issuance of the Notes.

5.NEW YORK LAW TO GOVERN.  THIS SUPPLEMENTAL INDENTURE AND ANY CLAIM, CONTROVERSY OR DISPUTE ARISING UNDER OR RELATED TO 

 

 

THIS SUPPLEMENTAL INDENTURE SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK. 

6.Counterparts.  The parties may sign any number of copies of this Supplemental Indenture.  Each signed copy shall be an original, but all of them together represent the same agreement.

7.Effect of Headings.  The Section headings herein are for convenience only and shall not affect the construction hereof.

8.The Trustee.  The Trustee shall not be responsible in any manner whatsoever for or in respect of the validity or sufficiency of this Supplemental Indenture or for or in respect of the recitals contained herein, all of which recitals are made solely by the Guaranteeing Subsidiaries and the Company.

 

 

 

IN WITNESS WHEREOF, the parties hereto have caused this Supplemental Indenture to be duly executed and attested, all as of the date first above written.

			
	
SYNEOS HEALTH, INC.

	
 
	
 
	
	
By:
	
 /s/ Jason Meggs
	
	
 
	
Name: Jason Meggs
	
	
 
	
Title: Chief Financial Officer
	
	
 
	
 
	
	
SHCR HOLDINGS CORPORATION
	
	
 
	
 
	
	
By: 
	
 /s/ Jonathan Olefson
	
	
 
	
Name: Jonathan Olefson
	
	
 
	
Title: Director 
	
	
 
	
 
	
	
SYNTERACTHCR HOLDINGS CORPORATION
	
	
 
	
 
	
	
By:
	
 /s/ Jonathan Olefson
	
	
 
	
Name: Jonathan Olefson
	
	
 
	
Title: Director 
	
	
 
	
 
	
	
SYNTERACTHCR CORPORATION
	
	
 
	
 
	
	
By:
	
 /s/ Jonathan Olefson
	
	
 
	
Name: Jonathan Olefson
	
	
 
	
Title: Director 
	
	
 
	
 
	
	
SYNTERACT, INC.
	
	
 
	
 
	
	
By: 
	
 /s/ Sara Epstein
	
	
 
	
Name: Sara Epstein
	
	
 
	
Title: Director
	
	
 
	
 
	
	
CU-TECH, L.L.C.
	
	
 
	
 
	
	
By:
	
 /s/ Sara Epstein
	
	
 
	
Name: Sara Epstein
	
	
 
	
Title: Manager
	
	
 
	
 
	
	
KENDLE NC LLC
	
	
 
	
 
	
	
By:
	
 /s/ Jonathan Olefson
	
	
 
	
Name: Jonathan Olefson
	
	
 
	
Title: Director
	

 

 

 

			
	

KINAPSE, INC.

	
 
	
 
	
	
By:
	
 /s/ Jonathan Olefson
	
	
 
	
Name: Jonathan Olefson
	
	
 
	
Title: Director
	
	
 
	
 
	
	
SYNEOS HEALTH INVESTMENT, LLC
	
	
 
	
 
	
	
By: 
	
 /s/ Jonathan Olefson
	
	
 
	
Name: Jonathan Olefson
	
	
 
	
Title: Manager 
	
	
 
	
 
	
	
 
	
 
	

 

 

 

 

			
	
WELLS FARGO BANK, NATIONAL ASSOCIATION,

  as Trustee

	
 
	
 
	
	
By:
	
 /s/ Todd Landry
	
	
 
	
Authorized Signatory
	
	
 
	
Todd Landry
	
	
 
	
Vice President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00332-of-00352.parquet"}]]